Partow Kebriaei, M.D.
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
About Dr. Partow Kebriaei
Dr. Kebriaei received her B.S. degree from Yale University in 1993, and her M.D. degree from the University of Texas at Houston medical school in 1997. She went on to receive her Internal Medicine training at University of Texas Southwestern in Dallas, and completed a fellowship in Hematology and Oncology at the University of Chicago in 2000. She joined the stem cell transplant department at MD Anderson Cancer Center (MDACC) in 2003. Dr. Kebriaei’s research interests include therapy of leukemias, in particular acute lymphoblastic leukemia (ALL), and she has led the development of the transplant program in ALL. She is also interested in the development of novel transplant preparative regimens that may have less regimen-related toxicity, and increased disease efficacy. More specifically, she is interested in investigating the use of traditional chemotherapeutic agents in combination with cellular therapies and adoptive immunotherapy to develop more effective treatment regimens. Work toward this aim includes investigating the use CD19-directed T cell therapy for lymphoid malignancies, and investigating the use of mesenchymal stromal cells for the therapy of graft versus host disease. Finally, she has been involved in the development of the CARTOX committee, a cross-disciplinary committee to oversee the safe administration of cellular therapy treatments. Dr. Kebriaei is actively involved in current phase I/II clinical trials at MDACC, has authored numerous reviews, book chapters, and papers, and serves as a reviewer for major hematology and oncology publications. She is an active member of hematology and oncology professional societies including American Association for Cancer Research, American Society of Hematology, American Society of Clinical Oncology, and American Society for Blood and Marrow Transplantation.
Present Title & Affiliation
Primary Appointment
Clinic Medical Director, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1997 | The University of Texas Health Science Center, Houston, Texas, US, MD |
| 1993 | Yale University, New Haven, Connecticut, US, Biology, BS |
Postgraduate Training
| 2021-2022 | Leading Teams Core Curriculum, Leadership Skills and Development, MD Anderson Leadership Institute, Houston, Texas |
| 2000-2003 | Hematology/Oncology Fellowship, Everett Vokes, M.D, University of Chicago Medical Center, Chicago, Illinois |
| 1998-2000 | Internal Medicine Residency, Daniel W. Foster, M.D, University of Texas Southwestern Medical Center, Dallas, Texas |
| 1997-1998 | Internal Medicine Internship, Daniel W. Foster, M.D, University of Texas Southwestern Medical Center, Dallas, Texas |
Licenses & Certifications
| 2007 | Texas Medical License |
| 2004 | Hematology |
| 2003 | Medical License Illinois |
| 2003 | Medical Oncology |
| 2001 | Internal Medicine |
Experience & Service
Faculty Academic Appointments
Associate Professor, Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2009 - 2015
Assistant Professor, Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2009
Administrative Appointments/Responsibilities
Director, Clinical Research Training Course, Center for International Blood and Marrow Transplant Research, Park City, Utah, 2024 - Present
Fellowship Program Associate Director, Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present
Cancer Medicine Director, Cancer Network, Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present
Other Professional Positions
Vice Chair of the CIBMTR Data and Safety Monitoring Board (DSMB), Research Collaboration Between The Medical College of Wisconsin and NMDP, CIBMTR, 2024 - Present
CPSS Messenger Council, University of Texas MD Anderson Cancer Center, Houston, Texas, 2024 - 2024
Wellness Champions, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, 2023 - 2024
Member Executive Committee Faculty Senate (ECFS), University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2024
Division Professionalism Ambassador (DPA), University of Texas MD Anderson Cancer Center, Houston, Texas, 2022 - Present
Member, Center International Blood and Marrow Transplant Research, Resource for clinical investigation in blood and marrow transplantation (CIBMTR RCI BMT) Data Safety Monitoring Board (DSMB), Philadelphia, PA, 2022 - 2025
Faculty Mentoring Initiative Committee Member, University of Texas MD Anderson Cancer Center, Houston, Texas, 2021 - Present
Co-Chair of Acute Leukemia Working Committee, Center for International Blood and Marrow Transplant Research, Houston, Texas, 2019 - 2024
Member, CIDR Executive Council Member, Center for International Blood and Marrow Transplant Research, Houston, Texas, 2019 - 2022
Committee Member Lymphoma/Myeloma faculty recruitment, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2019 - Present
Member, National Marrow Donor Program Institutional Review Board, Houston, Texas, 2018 - Present
Lead Workgroup Physician, Scripps/MD Anderson Collaboration, Houston, Texas, 2018 - Present
Mentor, University of Texas MD Anderson Cancer Center, Houston, Texas, 2018 - Present
Faculty Mentor, Clinical Research Training Course, Center for International Blood and Marrow Transplant Research, Park City, Utah, 2017 - Present
Lead, Data Group, CARTOX Committee, University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - Present
Intramural Institutional Committee Activities
Member, Clinical Faculty Review Committee-Promotions (CFRC-P), The University of Texas MD Anderson Cancer Center, 2025 - Present
Extramural Institutional Committee Activities
Member, Graduate Medical Education Committee (GMEC), The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2018 - Present
Member, Credentials Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2020
Member, CARTOX Committee, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Institutional Pre-Recombinant Advisory Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Chairperson, Acute & Critical Care Subcommittee, The University of Texas MD Anderson Cancer Center, 2012 - Present
Member, Medical Practice Committee, The University of Texas MD Anderson Cancer Center, 2010 - Present
Chairperson, Intensive Care Unit Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2012
Associate Member, Institutional Review Board 5, The University of Texas MD Anderson Cancer Center, 2008 - 2012
Member, Medical Records Committee, The University of Texas MD Anderson Cancer Center, 2008 - Present
Chairperson, Clinical Research Committee I, The University of Texas MD Anderson Cancer Center, 2008 - 2011
Member, Council of Committee Chairs, The University of Texas MD Anderson Cancer Center, 2007 - Present
Vice Chair, Intensive Care Unit Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2010
Member, Clinical Research Committee 3, The University of Texas MD Anderson Cancer Center, 2006 - 2007
Member, Intensive Care Unit Committee, The University of Texas MD Anderson Cancer Center, 2005 - 2007
Member, Clinical Research Committe I, The University of Texas MD Anderson Cancer Center, 2004 - 2007
Editorial Activities
Editorial Board, Leukemia & Lymphoma, 2020 - 2026
Associate Editor, Advances in Cell and Gene Therapy, 2017 - Present
Editoral Review Board Member, Journal of Cancer Therapeutics-and-Research, 2011 - Present
Editoral Review Board Member, World Journal of Stem Cells, 2011 - Present
Editoral Review Board Member, Chemotherapy, 2011 - Present
Editoral Review Board Member, Frontiers in Hematology Oncology, 2010 - Present
Honors & Awards
| 2021 | FY21 Gerald P. Bodey Award for Excellence in Education, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center |
| 2021 | The Presidents’ Recognition of Faculty Excellence: Faculty Honoree for Education and Mentorship Advancement, University of Texas MD Anderson Cancer Center |
| 2019 | Waun Ki hong Award for Excellence in Team Science in ALL, University of Texas MD Anderson Cancer Center |
| 2017 | Waun Ki Hong Award for Excellence in Team Science in CAR T Therapy, University of Texas MD Anderson Cancer Center |
| 2011 | Mid-Career Women Faculty Professional Development, Women Faculty Programs, University of Texas MD Anderson Cancer Center |
| 2003 | Merit Award, American Society of Clinical Oncology |
| 2002 | Molecular Biology Workshop, American Association for Cancer Research |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. Role of Stem Cell Transplant in ALL. SCTCT Department Meeting. Houston, Texas, US.
- 2024. Transplant in ALL, Who, and When. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2024. ALL 2024 Progress and challenges. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2023. Virtual: Transplant Basics: Risk Stratification for ALL. Invited. ASTCT. Houston, TX, US.
- 2023. ALL. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2022. Virtual: Banner SCT MDP Presentation Meeting. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2022. 2021-0428 and 2019-1122. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2021. ALL Transplant Program. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2021. Risk of infection after use of tocilizumab for GVHD prophylaxis in CB transplant. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2021. ALL Transplant Program. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2021. Acute lymphoblastic leukemia, update on indications and outcome. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2021. Driving CAR T cells for Hematologic Malignancies. Conference. Cigna, US.
- 2021. AML Second Transplant Outcomes. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2021. Transplant in ALL. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2020. 19.20.22 DuoCAR. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. SCT and CAR-T. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. CAR T-cell Outpatient Plan. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2019. ALL Transplant Program Update. Conference. University of Texas MD Anderson Cancer CEnter. Houston, TX, US.
- 2018. Updates in CAR T Therapies. Conference. Physicians' Educaiton Resource, LLC (PER). Houston, TX, US.
- 2018. A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia. Conference. Univeristy of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. Fucosylated MSC for treatment of steroid refractory GVHD. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. CAR T “Sleeping Beauty” trials. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. Complications of transplant. Conference. Prime Oncology. Houston, TX, US.
- 2017. 2017-0908: Infusion of Minimally Expanded CD19+ Specific Chimeric Antigen Receptor T cells for Patient with Advanced Lymphoid Malignancies. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. Neurotoxicity following CAR-NK. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. 2016-1097 A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB*04:01 Positive Subjects with Advance Cancers. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. CAR-T Cell Strategies: Overcoming The Challenges and New Strategies. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2017. FACT Training and Competency. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Busulfan (Bu) in combination with double nucleoside analogues Fludarabine (Flu) and Clofarabine (Clo) and plus Vorinostat as a Novel Reduced Toxicity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Leukemia. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Comparison of total body irradiation-based with intravenous busulfan-based chemotherapy-only conditioning regimens for myeloablative hematopoietic cell transplantation (HCT) in adults with acute lymphoblastic leukemia. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Transplant in ALL. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. "Promise and peril of CAR T cell therapy: CARTOX guidelines for toxicity management”. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. CAR-T toxicities and management. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. VOD Guidelines. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Stem Cell Transplant and Cellular Therapy to Treat Cancer. Conference. University of Houston-Clear Lake. Pearland, TX, US.
- 2016. ALL 2016 The Transplant Perspective. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Transplant and Role of CAR-T Cell Therapy. Conference. Axess Oncology and University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2016. Transplant, VOD Management, and Role of CAR-T Cell Therapy in ALL. Conference. Axess Oncology. Houston, TX, US.
- 2015. Management of Adverse Reaction to Infusion of T Cells and NK Cells. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. MRD Detection in ALL Role of pre and post Tx therapies. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Post Transplant CNS Prophylaxis. Conference. University of Texas MD Anderson Cancer Center. Hosuton, TX, US.
- 2015. Transplant for ALL. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Adoptive therapy using chimeric antigen receptor (CAR) modified T cells or expanded NK cells for the treatment of advanced hematologic malignancies. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2015. Phase 3 pivotal trial of lomab-B (lodine-131 Radiolabeled BC8 (Anti-CD45) Antibody in relapsed and refractory AML. Conference. University of Texas MD Anderson Cancer Center. Housotn, TX, US.
- 2014. Recent Developments in Acute Lymphoblastic Leukemia. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. ALL. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Trials Utilizing Chimeric Antibody Receptors (Cars) Driving Immunotherapy in ALL. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Acute Lymphoblastic Leukemia Defining the Optimal Time and Cell Source for HCT. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2014. Update on Clinical Trials Utilizing Sleeping Beauty and aAPCs to Manufacture CD19-directed CAR. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2013. Advances in Hematopoietic Stem Cell Transplantation. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2012. SCT Preparative Regimens. Conference. University of Texas M.D. Andreson Cancer Center. Houston, TX, US.
- 2012. Busulfan is Better. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2011. Allogeneic Stem Cell Transplantation for CML Resistant to Tyrosine Kinase Inhibitors. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2010. Therapy for Acute Lymphoblastic Leukemia. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2021. Transplantation for ALL. Conference. University of California Irvine. Orange, CA, US.
National Presentations
- 2025. Cord Tissue derived mesenchymal stromal cells (MSCs) for GVHD and regenerative medicine. Invited. 2025 Tandem Meetings of ASTCT and CIBMTR. Honolulu, Hawaii, US.
- 2024. Adult ALL Advancements: Optimizing Cure in 2024. Invited. 66th ASH Annual Meeting. San Diego, California, US.
- 2023. Abstract: Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia-Retrospective Dual-Center Study. Conference. American Society of Hematology (ASH). San Diego, CA, US.
- 2023. How I Select Patients for Transplant. Invited. ASH Meeting on Hematologic Malignancies. Chicago, IL, US.
- 2023. CNS Prophylaxis in ALL. Invited. Society of Hematologic Oncology (SOHO 2023. Houston, TX, US.
- 2023. Clinical Research Training Course. Invited. American Society for Transplantation and Cellular Therapy (ASTCT). Park City, UT, US.
- 2023. CAR-T Cells and T-Cell Receptor Cells in Solid Tumors. Invited. FACT IEC Webinar. Houston, TX, US.
- 2023. ALL 2023: Progress and challenges. Invited. Virtual:Enjoy Science Webinar Series. Houston, TX, US.
- 2022. Virtual Recording: Mitigating VOD Risk in Patients Treated for R/R ALL. Invited. Academy for Continued Healthcare Learning. Houston, TX, US.
- 2022. Virtual: 2022 AcCELLerate Forum. Invited. ASTCT Clinical Education Conference. Houston, TX, US.
- 2022. Virtual: What are the patient and clinical considerations when selecting therapy for R/R B-cell lineage ALL?. Invited. Academy for Continued Healthcare Learning (ACHL). Chicago, IL, US.
- 2022. Virtual Podcast: The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 with Complete Molecular Remission: A Retrospective Analysis. Invited. ASH’s Editorial Team for The Hematologist and Editor-in-Chief Dr. Laura Michaelis. Houston, TX, US.
- 2022. How Do I Treat Relapsed B-ALL with Antibody-Based Therapy or CAR T cells?. Invited. Meeting on Hematologic Maliganancies. Chicago, IL, US.
- 2022. Clinical Research Training Course. Invited. ASTCT. Park City, UT, US.
- 2022. Virtual: BMT Steering Committee. Invited. CIBMTR. Houston, TX, US.
- 2022. Virtual: CAR T-cells in ALL and DLBCL – an update on the trials. Invited. SASMO/SASCeTS 2022: Conference. Houston, TX, US.
- 2022. CIBMTR Working Committee, Acute Leukemia. Invited. 2022 Tandem Meetings|Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Salt Lake City, UT, US.
- 2021. Virtual: 63rd ASH Annual Meeting VIP Presentation Speaker. Invited. American Society of Hematology. Houston, TX, US.
- 2021. Virtual: Transplant for Acute Leukemias. Invited. Medscape Education. Houston, TX, US.
- 2021. Virtual: How I treat Ph+Acute Lymphoblastic Leukemia. Invited. American Society of Hematology on Hematologic Malignancies. Houston, TX, US.
- 2021. Virtual: SOHO Meeting Approach to Philadelphia Chromosome Positive ALL. Invited. University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2021. Virtual: Management of B-ALL in the Era of Targeted Immunotherapy. Invited. OE Oncology Education, US.
- 2021. Satellite Symposium: Rapid Fire Live Tumor Board: Leveraging Clinical Data on CAR T to Inform Treatment Decision Making Across Heme Malignancies. Invited. Physician Education Resource. Houston, TX, US.
- 2021. Virtual: Novel targeted immunotherapy in B-ALL: The promise and perils. Invited. Cell Therapy Transplant Canada (CTTC) Webinar Series. Houston, TX, US.
- 2021. Virtual Bridge to Transplant: Clinical Consideratons for Transplant in Older Patients with AML. Invited. Medscape Live Webinar. Houston, TX, US.
- 2021. Virtual: Bridge to Transplant: Clinical Considerations for Transplant in Older Patients with AML. Invited. Medscape Live Webinar. Houston, TX, US.
- 2021. Virtual: ALL 2021: The Transplanter’s Perspective. Invited. HSCTCT Grand Rounds at University of California Irvine. Houston, TX, US.
- 2021. Clinical Management of CAR-T. Invited. LifeSource Virtual Conference Series: Session 2, US.
- 2021. INO-VATE ALL Data Review. Invited. Pfizer. Houston, TX, US.
- 2020. Current Treatment Practice on Adult ALL and perception about Inotuzumab. Invited. Pfizer India. Houston, TX, US.
- 2020. Virtual: Deep dive in INOVATE trial data. Invited. Pfizer India. Houston, TX, US.
- 2020. Virtual: Cell Therapy for Solid Tumors-Task Force Report. Invited. CIBMTR. Houston, TX, US.
- 2020. Virtual: The Importance of MRD assessment in acute leukemia: Pre-and Post- hematopoietic stem cell transplantation. Invited. Teharan University of Medical Sciences. Houston, TX, US.
- 2020. Cell Therapy in Acute Lymphoblastic Leukemia. Invited. CLAS meeting. Houston, TX, US.
- 2020. Virtual: “Differing Perspectives Session: Who to Transplant: AML, ALL, MDS”. Invited. 2020 ASH Meeting on Hematologic Malignancies. Houston, TX, US.
- 2020. How I Treat Ph+ ALL in Adult Post-CR1. Invited. Saudi Society of Blood & Marrow Transplantation Webinar Series. Houston, TX, US.
- 2020. BlinatumomabIs Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia. Invited. ASTCT and CIBMTR. Orlando, FL, US.
- 2019. Is Transplant Still Necessary in the Era of Targeted Cellular Therapy for ALL? PRO. Invited. Society of Hematologic Oncology. Houston, TX, US.
- 2019. Targeted Cellular Therapy for ALL. Invited. Society of Hematologic Oncology. Houston, TX, US.
- 2019. The untapped power of patient registries for your manufacturing process. Invited. Phacilitate:Exchange. Miami, FL, US.
- 2018. A guideline for the potent neurotoxic side effects of CAR-T therapy. Invited. omi oncology meeting innovations. Dallas, TX, US.
- 2017. Session Moderator:Engraftment, and Acute Transplant Toxicities: Alternative Donor Transplant. Invited. American Society of Hematology (Moderator). Atlanta, GA, US.
- 2017. Role of Remission Status and Prior Transplant in Optimizing Survival Outcomes Following Allogeneic Hematopoietic Stem Transplantation (HSCT) in Patients Who Received Inotuzumab Ozogamicin (INO) for Relapsed / Refractory (R/R) Acute Lymphoblastic Leukemia (ALL). Invited. American Society of Hematology (Oral). Atlanta, GA, US.
- 2017. Long Term Follow up after Adoptive Transfer of CD19-Specific CAR+�T Cells Genetically Modified via Non-Viral Sleeping Beauty System Following Hematopoietic Stem Cell Transplantation (HSCT). Conference. American Society of Hematology (Poster). Atlanta, GA, US.
- 2017. Shortening the Time to Manufacture CAR+ T Cells with Sleeping Beauty�System Supports T-Cell Engraftment and Anti-Tumor Effects in Patients with Refractory CD19+�Tumors. Conference. American Society of Hematology (Poster). Atlanta, GA, US.
- 2015. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. Conference. American Society of Hematology. Orlando, FL, US.
- 2015. Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies. Conference. American Society of Hematology. Orlando, FL, US.
- 2015. From Pediatric to Adult Lymphoblastic Leukemia: A common Strategy for a Cure. Invited. Society for Adolescent and Young Adult Oncology. Newport Beach, CA, US.
- 2013. First Clinical Trials Employing Sleeping Beauty System and Artificial Antigen Presenting Cells to Generate T cells Expressing CD19-specific Chimeric Antigen Receptor. Conference. American Society of Hematology. Dallas, TX, US.
- 2013. First-in-Human Application of Sleeping Beauty System for Gene Therapy. Conference. American Society of Gene and Cellular Therapy. Salt Lake City, UT, US.
- 2013. Is there a role of mesenchymal stromal cells in patients with graft versus host disease?. Invited. 2013 BMT Tandem Meetings. Salt Lake City, UT, US.
- 2012. MultiStem GVHD. Invited. Athersys, Inc. San Diego, CA, US.
- 2011. Therapy of Adults with Acute Lymphoblastic Leukemia. Invited. Seventh Annual Oncology Congress. San Francisco, CA, US.
- 2010. Therapy of Adults with Acute Lymphoblastic Leukemia. Invited. Global Initiative. Houston, TX, US.
- 2009. Mesechymal Stem Cells for the Treatment of Graft versus Host Disease. Invited. ISCT Somatic. Bethesda, MD, US.
- 2006. Busulfan and Melphalan is an effective transplant preparative regimen for lymphoid malignancies. Invited. BMT Tandem Meetings, US.
International Presentations
- 2025. Current data on obecabtagene autoleucel in ALL. Invited. Global Summit on Hematologic Malignancies. Whistler, BC, CA.
- 2025. Where will allogeneic transplant land in high-risk ALL?. Invited. Global Summit on Hematologic Malignancies. Whistler, BC, CA.
- 2023. CAR T in ALL. Invited. Abu Dhabi Stem Cells Center (ADSCC). Abu Dhabi, AE.
- 2023. Maintenance Therapy After Allogeneic Transplant in Acute Lymphoblastic Leukemia. Invited. Japanese Society of Hematology (JSH). Tokyo, JP.
- 2022. Real World Data: CARs in ALL. Invited. Medical City Abu Dhabi. Dubai, AE.
- 2021. Virtual: ISCT Modified T-Cells Therapies for Hematologic Malignancies and Solid Tumors. Invited. International Society Cell & Gene Therapy. Houston, US.
- 2019. Immunotherapy in Acute Lymphoblastic Leukemia. Invited. National Hematology Association of Argentina. Buenos Aries, AR.
- 2018. CAR T cell therapy for acute leukemia. Invited. O-Tours d.o.o. Dubrovnik, HR.
- 2018. Landscape of acute lymphoid leukemia. Invited. International Academic Oncology Meetings. Cancun, MX.
- 2018. Chimeric antigen receptor (CAR) therapy. Invited. Sapienza University of Rome.
- 2016. Minimal residual disease pre and postrasplantation. Invited. Instituto Nacional de Cancerologia Mexico. Cancun, MX.
- 2016. Haplo Identical Transplantation (MD Anderson Data). Invited. 3rd International Annual Congress on Hematopoietic Stem Cell Transplantation and 1st International Congress of Nursing. Tehran, IR.
- 2016. Maintenance chemotherapy in ALL ph+and high risk patients post HSCT. Invited. 3rd International Annual Congress on Hematopoietic Stem Cell Transplantation and 1st International Congress of Nursing. Tehran, IR.
- 2016. Treatment strategy in patient with recurrent acute leukemia after allogeneic HSCT. Invited. 3rd International Annual Congress on Hematopoietic Stem Cell Transplantation and 1st International Congress of Nursing. Tehran, IR.
- 2015. Car-T Cells ain hematological Malignancies. Invited. National Cancer Institute of Mexico. Cancun, MX.
- 2014. Conditioning regimen for ALL including Busulfex, Clofarabine. Invited. Otsuka Pharmaceutical Co Ltd. Fukuoka, JP.
- 2014. Conditioning regimen for ALL including Busulfex, Clofarabine. Invited. Otsuka Pharmaceutical Co Ltd. Hiroshima, JP.
- 2014. Conditioning regimen for ALL including Busulfex, Clofarabine. Invited. Otsuka Pharmaceutical Co Ltd. Okinawa, JP.
- 2013. Solving the dilema how can we predict por harvests cells ad solve them Update on plerixafor. Conference. Instituto Nacional de Cancerologia. Cancun, MX.
- 2013. Personalizing the Conditioning Regimen. Conference. Instituto Nacional de Cancerologia. Cancun, MX.
- 2013. Transplants in Myeloproliferative Neoplasms. Conference. Instituto Nacional de Cancerologia. Cancun, MX.
- 2013. FIRST CLINICAL TRIALS EMPLOYING SLEEPING BEAUTY SYSTEM AND ARTIFICIAL ANTIGEN PRESENTING CELLS TO GENERATE T CELLS EXPRESSING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR. Conference. European Hematology Association (EHA), SE.
- 2012. The role of transplant and maintenance therapy in Ph+ALL. Invited. THe Conference Hematoncology. Cancun, MX.
- 2012. TBI versus Chemotherapy Only Preparative Regimens for SCT/The role of transplant and maintenance therapy in Ph+ALL. Invited. The Conference Hematonocology. Cancun, MX.
- 2011. Mesenchymal Stromal Cells for the Therapy of Graft versus Host Disease. Invited. First Annual Congress on Stem Cell Research. Sakarya, TR.
- 2011. The Role of Mesenchymal Stromal Cells for the Treatment of Graft versus Host Disease. Invited. BMT Tandem Meetings. Honolulu, US.
- 2010. Cellular Therapy for the Treatment of B-cell Malignancies. Invited. Mexican Society of Hematology. Cozumel, MX.
- 2010. The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Invited. Mexican Society of Hematology. Cozumel, MX.
- 2010. The Role of Hematopoietic Stem Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Invited. The Medal Group, LLC. Singapore City, SG.
- 2009. Addition of cord blood to reduced intensity conditioning to augment graft versus tumor effect. Invited. CME Program. Los Angeles, US.
Formal Peers
- 2022. Real World Data: CARs in ALL. Invited. Dubai, AE.
- 2020. The Importance of MRD Assessment in Acute Leukemia ;Pre and Post Hematopoietic Stem Cell Transplantation. Visiting. Tehran, IR.
- 2019. Immunotherapy in ALL: Monoclonal antibodies, BiTes and antibody-drug Conjugate/Car T Cells/ Role of allogeneic transplantation and maintenance therapy. Invited, AR.
- 2019. Inotuzumab´s AE management. Invited, SG.
- 2018. Optimizing the Treatment of Hematologic Malignancies With HSCT. Visiting. Temple, TX, US.
- 2018. Adoptive Cell-Based Cancer Immunotherapy Symposium. Invited. San Francisco, CA, US.
- 2018. CAR T cell therapy for hematologic malignancies. Invited. Lake Success, NY, US.
- 2017. Transplantation in ALL. Invited. Houston, TX, US.
- 2015. CIBMTR Cellular Therapy Registry Forum. Invited. Milwaukee, WI, US.
- 2015. Current and Future CAR therapies for ALL and Myeloma. Invited. San Diego, CA, US.
Grant & Contract Support
| Date: | 2026 - 2031 |
| Title: | Novel Cord Blood Cellular Therapies |
| Funding Source: | NIH |
| Role: | Co-I |
| Date: | 2021 - 2026 |
| Title: | Phase I/II, Dose-Escalation Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) And Myelodysplasia-Excess Blasts (MDS-EB) |
| Funding Source: | Magenta Therapeutics |
| Role: | PI |
| ID: | #60266 |
| Date: | 2019 - 2022 |
| Title: | Celgene Cellular Therapy Fellowship |
| Funding Source: | Celgene |
| Role: | PI |
| Date: | 2018 - 2025 |
| Title: | Novel Cord Blood Derived Cellular Therapies |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5P01CA148600-11 |
| Date: | 2017 - 2020 |
| Title: | A Phase I Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells(KITE-718) in HLA-DP1*04:01 Positive subjects with Advanced Cancers |
| Funding Source: | KITE Pharmaceuticals |
| Role: | PI |
| ID: | CS2017-00053988 |
| Date: | 2017 - 2020 |
| Title: | A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant |
| Funding Source: | Jazz Pharmaceuticals |
| Role: | PI |
| ID: | CS2017-00053576 |
| Date: | 2017 - 2023 |
| Title: | A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation vs Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia |
| Funding Source: | Actinium Pharmaceuticals |
| Role: | PI |
| ID: | 52529 |
| Date: | 2016 - 2021 |
| Title: | Redirected T Cell Therapy to Cure Invasive Fungal Infections |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2016 - 2023 |
| Title: | Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients with Acute Lymphoblastic Leukemia |
| Funding Source: | Amgen Pharmaceutical |
| Role: | PI |
| ID: | 5117 |
| Date: | 2015 - 2021 |
| Title: | CD19+ Chimeric Antigen Receptor T Cells for Patients with Advanced Lymphoid Malignancies |
| Funding Source: | Ziopharm Inc |
| Role: | PI |
| Date: | 2013 - 2016 |
| Title: | Manufacture and Deployment of Universal T Cells |
| Funding Source: | Alliance for Cancer Gene Therapy |
| Role: | Co-I |
| ID: | CP8505 |
| Date: | 2012 - 2017 |
| Title: | Rendering T Cells as Drugs |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01OD011540-01 |
| Date: | 2012 - 2017 |
| Title: | Imaging T Cells by Positron Emission Tomography |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1-R01-CA163587-01A1 |
| Date: | 2011 - 2014 |
| Title: | Off-The-Shelf Immunotherapy for follicular lymphoma infusing CD19-Specific T Cells |
| Funding Source: | Lymphoma Research Foundation |
| Role: | Co-I |
| ID: | 213575 |
| Date: | 2011 - 2013 |
| Title: | A Phase III Trial Comparing a Combination of IV Bulsulfan with High-Dose Melphalan (Bu-Mel 140) with High-Dose Melphalan (Mel 200) Alone for Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma |
| Funding Source: | Otsuka Pharmaceutical, Inc |
| Role: | Co-I |
| ID: | CS2010-00032635 |
| Date: | 2010 - 2015 |
| Title: | T-Cell Therapy For B-Lineage Acute Lymphoblastic Leukemia |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA141303 |
| Date: | 2009 - 2013 |
| Title: | Busulfan plus clofaradine followed by allogeneic hematopoietic stem cell transplantation for patients with all, lymphoma or bihenotypic leukemia-CT |
| Funding Source: | Otsuka |
| Role: | PI |
| ID: | CS2009-0029583JW01 |
| Date: | 2007 - 2013 |
| Title: | Adoptive Immunotherapy after umbilical cord blood transplant |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA124782 |
| Date: | 2007 - 2013 |
| Title: | UCB-Derived CD19-Specific T Cells for Universal Treatment of B-Cell Malignancy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R33 CA116127 |
| Date: | 2007 - 2010 |
| Title: | UCB-derived CD19-specific T Cells for Universal Treatment of B-cell Malignancies |
| Funding Source: | National Institute of Allergy and Infectious Diseases/ DHHS/NIH |
| Role: | Co-I |
| ID: | 5-R21-CA116127 |
| Date: | 2007 - 2011 |
| Title: | Enhancing the Efficacy of CD19-Specific Cord Blood-Derived T Cells |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01 CA120956 |
| Date: | 2006 - 2009 |
| Title: | A Phase III Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) Infusion for the Treatment of Steroid Refractory Acute GVHD |
| Funding Source: | Osiris Therapeutics, Inc |
| Role: | PI |
| ID: | CS2007-0018847LE |
| Date: | 2006 - Present |
| Title: | Transplant Therapy Program for Acute Lymphoblastic Leukemia |
| Funding Source: | NIH Loan Repayment Program |
| Role: | PI |
| Date: | 2005 - 2008 |
| Title: | Phase II Study of Depocyt Therapy For CNS Prophylaxis in High-Risk Patients After Hematopoietic Stem Cell Transplant |
| Funding Source: | ENZON, Inc |
| Role: | PI |
| ID: | CS2005-00013681LE |
| Date: | 2005 - 2006 |
| Title: | A Phase II, Double Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety And Efficacy of Prochymal |
| Funding Source: | Osiris Therapeutics, Inc |
| Role: | PI |
| ID: | CS2005-00014190LE |
| Date: | 2005 - 2009 |
| Title: | A Long-Term Follow-up Study to Evaluate the Safety of Prochymal (Ex-vivo Cultured Adult Human Mesenchymal Stem Cells) for the Treatment of Acute Graft Versus Host Disease in Subjects who receive Allogeneic Hematopoietic Stem Cell transplantation |
| Funding Source: | Osiris Therapeutics, Inc |
| Role: | PI |
| ID: | CS2005-00014193LE |
Selected Publications
Peer-Reviewed Articles
- Mehta, RS, Aljawai, YM, Kebriaei, P, Cao, K, Zou, J, Carmazzi, Y, Rondon, G, Oran, B, Popat, UR, Rezvani, K, Champlin, RE, Shpall, E. Development and explainable AI-driven characterization of a prognostic model for haploidentical transplantation outcomes. npj Digital Medicine 9(1), 2026. e-Pub 2026. PMID: 41772139.
- Kantarjian, HM, Qiao, W, Jain, N, Jen, WY, Kugler, E, Short, NJ, Garris, R, Pierce, S, Kebriaei, P, Wang, SA, Haddad, FG, Ravandi-Kashani, F, Huang, X, Jabbour, EJ. Outcome of second-line therapy in adult B-cell acute lymphoblastic leukemia. Cancer 132(8), 2026. e-Pub 2026. PMID: 41954167.
- Marcoux, C, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Saeed, A, Haider, A, Ramdial, JL, Irfan, S, YagoNieto, Tang, G, Aljawai, YM, Kebriaei, P, Lee, HC, Patel, K, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH, Pasvolsky, O. Post-transplant outcomes in IgD multiple myeloma:a propensity score-matched analysis. Transplantation and Cellular Therapy 32(4):429.e1-429.e4, 2026. e-Pub 2026. PMID: 41421540.
- Smallbone, PI, Mendt Vilchez, MC, Sackstein, R, Tanner, MR, Kaur, I, Basar, R, Rafei, H, Daher, M, Overman, B, Al-Atrash, G, Alousi, AM, Bashir, Q, Hosing, C, Im, JS, Kebriaei, P, Banerjee, PP, Patel, KP, Zou, J, Cao, K, Khouri, IF, Mehta, RS, Molldrem, JJ, Nieto, Y, Oran, B, Popat, UR, Qazilbash, MH, Rondon, G, Saini, N, Srour, S, Champlin, RE, Rezvani, K, Shpall, E, Olson, AL. Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftment. Cytotherapy 28(3), 2026. e-Pub 2026. PMID: 41396090.
- Pasvolsky, O, Marcoux, C, Milton, D, Haider, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Smallbone, PI, Lin, P, Ramdial, JL, Nieto, Y, Mohamedi, A, Siddiqui, U, Jamil, A, Tang, G, Aljawai, YM, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Results of delayed or salvage autologous hematopoietic stem cell transplantation for multiple myeloma. Bone marrow transplantation 61(3):294-302, 2026. e-Pub 2026. PMID: 41350936.
- Mehta, RS, Aljawai, YM, Kebriaei, P, Rondon, G, Fingrut, WB, Smallbone, PI, Oran, B, Olson, AL, Champlin, RE, Shpall, E. Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis. Leukemia 40(3):502-510, 2026. e-Pub 2026. PMID: 41526616.
- Subramanian, N, Garcia Pleitez, H, Nguyen, D, Milton, D, Kebriaei, P, Shpall, E, Cheng, L, Lu, J, Jin, S, Wu, CC, Sheth, RA, Ferrajoli, A, Hanzelka, KM, Kroll, M, Rojas Hernandez, CM. Automated natural language processing to identify venous thromboembolism from diagnostic imaging reports. Blood Vessels, Thrombosis and Hemostasis 3(1), 2026. e-Pub 2026. PMID: 41503124.
- Greenbaum, U, Hashmi, H, Elsawy, M, Kim, S, Moskop, A, Oloyede, T, Awan, FT, Bachanova, V, Badar, T, Bar, M, Barba, P, Beitinjaneh, AM, Cashen, A, Dholaria, B, Farooq, U, Foglesong, J, Ganguly, S, Hematti, P, Hill, LQ, Jain, MD, Jain, T, Kebriaei, P, Kittai, AS, Locke, FL, Lulla, P, McGuirk, J, Mead, E, Mussetti, A, Nishihori, T, Olson, AL, Pennisi, M, Perales, MA, Geethakumari, PR, Riedell, PA, Saber, W, Shouval, R, Shpall, EJ, Magalhaes-Silverman, M, Strouse, CS, Turtle, CJ, Vallurupalli, A, Wudhikarn, K, Pasquini, MC, Ahmed, S, Sorror, ML. New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma. Blood Advances 10(1):217-227, 2026. e-Pub 2026. PMID: 40811818.
- Mehta, RS, Aljawai, YM, Kebriaei, P, Hosing, C, Olson, AL, Oran, B, Popat, UR, Rondon, G, Rezvani, K, Champlin, RE, Shpall, E. Re-Evaluating Donor Selection Priorities for Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide. JCO Oncology Practice, 2026. e-Pub 2026. PMID: 41529219.
- Pasvolsky, O, Shimony, S, Saliba, RM, Marcoux, C, Ledesma, C, Rondon, G, Tewari, P, Ragoonanan, D, Short, NJ, Jabbour, EJ, Gooptu, M, Ho, VT, Soiffer, RJ, Antin, JH, Koreth, J, Cutler, C, Paolino, JD, Duncan, C, Lehmann, L, DeAngelo, DJ, Jain, N, Champlin, RE, Shpall, E, Luskin, MR, Kebriaei, P. Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia—A Retrospective, Dual-Center Study. American journal of hematology 101(1):16-25, 2026. e-Pub 2026. PMID: 41051170.
- Goulart, H, Ravandi-Kashani, F, Short, NJ, Jain, N, Daver, N, Kadia, TM, DiNardo, C, Borthakur, G, Takahashi, K, Pemmaraju, N, Haddad, FG, Montalban Bravo, G, Alvarado, Y, Issa, GC, Bataller Torralba, A, Pierce, S, Loghavi, S, Tang, G, Wang, S, Thakral, B, Shpall, E, Champlin, RE, Khouri, IF, Kebriaei, P, Garcia-Manero, G, Sasaki, K, Jabbour, EJ, Senapati, J. Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 41370732.
- Short, NJ, Jabbour, EJ, Macaron, W, Jain, N, Haddad, FG, Loghavi, S, Kadia, TM, Kebriaei, P, Kugler, E, Matthews, JA, Garris, R, Ravandi-Kashani, F, Kantarjian, HM. Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL. Blood cancer journal 15(1), 2025. e-Pub 2025. PMID: 41120271.
- Mehta, RS, Aljawai, YM, Kebriaei, P, Olson, AL, Oran, B, Rondon, G, Rezvani, K, Champlin, RE, Shpall, E. The Impact of Isolated HLA-DQB1 Mismatch and Donor Age in Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy 31(11):920.e1-920.e14, 2025. e-Pub 2025. PMID: 40819683.
- Aljawai, YM, Ramdial, JL, Smallbone, PI, Chen, GL, Kebriaei, P, Pasvolsky, O, Popat, UR, Oran, B, Rezvani, K, Champlin, RE, Shpall, E, Mehta, RS. Comparative outcomes of HSCT with posttransplant cyclophosphamide in older adults. Blood Advances 9(20):5201-5206, 2025. e-Pub 2025. PMID: 40795211.
- Strati, P, Brandt, AC, Lionel, A, Henderson, J, Westin, JR, Adkins, S, Shpall, E, Kebriaei, P, Ramdial, JL, Saini, N, Ahmed, S, Flowers, CR, Neelapu, SS, Hildebrandt, MA. Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy. Journal for immunotherapy of cancer 13(10), 2025. e-Pub 2025. PMID: 41067879.
- Marcoux, C, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Patel, A, Khan, HN, Ramdial, JL, Nieto, Y, Tang, G, Haider, A, Aljawai, YM, Kebriaei, P, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH, Pasvolsky, O. Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant. Transplantation and Cellular Therapy 31(10):804.e1-804.e9, 2025. e-Pub 2025. PMID: 40752590.
- Senapati, J, Kantarjian, HM, Kadia, TM, Kekedjian, J, Borthakur, G, Daver, N, DiNardo, C, Jabbour, EJ, Bose, P, Short, NJ, Yilmaz, M, Jain, N, Pemmaraju, N, Abbas, HA, Issa, GC, Maiti, A, Bravo, GM, Deshmukh, I, Shpall, E, Kebriaei, P, Popat, UR, Loghavi, S, Thakral, B, Tang, G, Haddad, FG, Alvarado, Y, Manero, GG, Ravandi-Kashani, F. Contemporary outcomes of octa-nonagenarians with newly diagnosed acute myeloid leukemia. Cancer 131(16), 2025. e-Pub 2025. PMID: 40772501.
- Aljawai, YM, Ramdial, JL, Rondon, G, Smallbone, PI, Kebriaei, P, Popat, UR, Oran, B, Rezvani, K, Champlin, RE, Shpall, E, Mehta, RS. Outcomes of haploidentical vs mismatched unrelated donor HCT with posttransplant cyclophosphamide prophylaxis. Blood Advances 9(15):4023-4036, 2025. e-Pub 2025. PMID: 40517414.
- Pasvolsky, O, Marcoux, C, Milton, D, Rafaeli, N, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Mohamedi, A, Deen, AF, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation. Transplantation and Cellular Therapy 31(8):565.e1-565.e9, 2025. e-Pub 2025. PMID: 40383197.
- Oran, B, Thall, PF, Alousi, AM, Al-Atrash, G, Mehta, RS, Marin, D, Kebriaei, P, Popat, UR, Bassett Jr, R, Bashir, Q, Im, JS, Olson, AL, Jewell, J, Smallbone, PI, Shpall, E, Champlin, RE. Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant. Haematologica 111(1):149-157, 2025. e-Pub 2025. PMID: 40702903.
- Meath, CJ, Simon, B, Mehta, RS, Kebriaei, P, Lin, JS. Terlipressin for sinusoidal obstruction syndrome-associated acute kidney injury. Clinical Kidney Journal 18(7), 2025. e-Pub 2025. PMID: 40661925.
- Shouval, R, Strouse, CS, Kim, S, Oloyede, T, Ahmed, S, Awan, FT, Luan, D, Bachanova, V, Badar, T, Bar, M, Barba, P, Beitinjaneh, AM, Cashen, A, Dholaria, B, Elsawy, M, Ganguly, S, Geethakumari, PR, Greenbaum, U, Hashmi, H, Hill, LQ, Jain, MD, Jain, T, Kebriaei, P, Kittai, AS, Locke, FL, Lulla, P, Mead, E, McGuirk, J, Mussetti, A, Nishihori, T, Olson, AL, Pennisi, M, Perales, MA, Riedell, PA, Saber, W, Mirza, AS, Magalhaes-Silverman, M, Shpall, E, Sorror, ML, Wudhikarn, K, Turtle, CJ, Moskop, A, Pasquini, MC. Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplantation and Cellular Therapy 31(7):419-433, 2025. e-Pub 2025. PMID: 40288610.
- Lontos, K, Saliba, RM, Kanagal Shamanna, R, Ozcan, G, Ramdial, JL, Chen, GL, Kadia, TM, Short, NJ, Daver, N, Kantarjian, HM, Marin, D, Kebriaei, P, Popat, UR, Champlin, RE, Shpall, E, Oran, B. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS/AML for transplantation. Blood Advances 9(11):2845-2854, 2025. e-Pub 2025. PMID: 39853269.
- Sharma, A, O'Brien, MM, Phillips, CL, Schultz, KR, Mehta, PA, Kebriaei, P, Vandendries, E, Dorman, S, Jiang, W, Zhang, F, Asomaning, K, Zhang, MJ, De Lima, M, Marks, DI, Saber, W. Sinusoidal obstruction syndrome and other outcomes in pediatric patients with acute lymphoblastic leukemia who received inotuzumab ozogamicin before hematopoietic cell transplantation. Journal of Clinical Oncology 43:e22000-e22000, 2025. e-Pub 2025.
- Pasvolsky, O, Abid, MB, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Jatoi, A, Khan, HN, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Siddiqui, U, Aljawai, YM, Kebriaei, P, Lee, HC, Patel, K, Gaballa, MM, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. British Journal of Haematology 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
- Alkhunaizi, M, Soto-Lanza, F, Leung, CH, Bhan, N, Bashoura, L, Dickey, BF, Sharifi, H, Cheng, GS, Yanik, G, Rondon, G, Saliba, RM, Chen, GL, Al-Atrash, G, Hosing, C, Kebriaei, P, Popat, UR, Shpall, E, Champlin, RE, Li, L, Alousi, AM, Sheshadri, A. Restrictive Ventilatory Defects Following Hematopoietic Stem Cell Transplant Are Associated With Increased Mortality. Transplantation and Cellular Therapy 31(4):255.e1-255.e10, 2025. e-Pub 2025. PMID: 39921208.
- Pasvolsky, O, Marcoux, C, Wang, Z, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Syed, N, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Ye, JC, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
- Marcoux, C, Pasvolsky, O, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Ahmed, A, Aljawai, YM, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplantation and Cellular Therapy 31(1):12.e1-12.e10, 2025. e-Pub 2025. PMID: 39448031.
- Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant. Blood Cancer J 14(1):4, 2024. e-Pub 2024. PMID: 38199987.
- Rahman ZA, Othman T, Saliba RM, Vanegas YAM, Mohty R, Ledesma C, Rondon G, Jain N, Jabbour E, Pullarkat V, Alkhateeb HB, Kantarjian HM, Greipp PT, Nakamura R, Kharfan-Dabaja MA, Champlin RE, Forman SJ, Shpall EJ, Litzow MR, Foran JM, Aldoss I, Koller PB, Kebriaei P. A Multicenter Analysis of Allogeneic Transplant Outcomes in Adults with Philadelphia-Like B-Cell Acute Lymphoblastic Leukemia in First Complete Remission. Transplant Cell Ther 30(12):1197-1205, 2024. e-Pub 2024. PMID: 39332807.
- Gui G, Ravindra N, Hegde PS, Andrew G, Mukherjee D, Wong Z, Auletta JJ, El Chaer F, Chen EC, Chen YB, Corner A, Devine SM, Iyer SG, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Dillon LW, Hourigan CS. Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplant 60(2):154-160, 2024. e-Pub 2024. PMID: 39506075.
- Pasvolsky O, Marcoux C, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Lee J, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Kebriaei P, Becnel MR, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Optimal infused CD34(+) cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood Cancer J 14(1):189, 2024. e-Pub 2024. PMID: 39482325.
- Gui G, Ravindra N, Hegde PS, Andrew G, Mukherjee D, Wong Z, Auletta JJ, El Chaer F, Chen EC, Chen YB, Corner A, Devine SM, Iyer SG, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Dillon LW, Hourigan CS. Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplant 60(2):144-153, 2024. e-Pub 2024. PMID: 39455897.
- Angelidakis G, Chemaly RF, Sahasrabhojane PV, Morado-Aramburo O, Jiang Y, Bhatti MM, Shpall E, Hosing C, Jain P, Mahadeo KM, Khawaja F, Elhajj P, Wargo JA, Jenq RR, Ajami NJ, Kebriaei P, Ariza-Heredia EJ. Humoral Immunity and Antibody Responses against Diphtheria, Tetanus, and Pneumococcus after Immune Effector Cell Therapies: A Prospective Study. Vaccines (Basel) 12(9), 2024. e-Pub 2024. PMID: 39340100.
- Gyurkocza B, Nath R, Seropian S, Choe H, Litzow MR, Abboud C, Koshy N, Stiff P, Tomlinson B, Abhyankar S, Foran J, Hari P, Chen G, Al-Kadhimi Z, Kebriaei P, Sabloff M, Orozco JJ, Jamieson K, Silverman M, Van Besien K, Schuster M, Law AD, Larkin K, Pandit-Taskar N, Rowley SD, Munshi P, Cook R, Levy MY, Lazarus HM, Sandmaier BM, Pagel JM, Reddy V, MacDougall J, McNamara K, Spross J, Haeuber E, Vusirikala M, Nahar A, Desai A, Giralt S. Randomized Phase III SIERRA Trial of (131)I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML. J Clin Oncol 43(2):201-213, 2024. e-Pub 2024. PMID: 39298738.
- Marcoux CM, Alousi AM, Im J, Hill LC, Smallbone P, Popat U, Hosing C, Kebriaei P, Olson A, Mehta R, Chen G, Qazilbash M, Shpall E, Champlin RC, Saliba RM. Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease. Bone Marrow Transplant 59(11):1594-1600, 2024. e-Pub 2024. PMID: 39187601.
- Mehta RS, Ramdial JL, Kebriaei P, Champlin RE, Popat UR, Rezvani K, Shpall EJ. Haploidentical versus HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations. Blood Adv 8(20):5306-5314, 2024. e-Pub 2024. PMID: 39167765.
- Dillon LW, Gui G, Ravindra N, Andrew G, Mukherjee D, Wong ZC, Huang Y, Gerhold J, Holman M, D'Angelo J, Miller J, Higgins J, Salk JJ, Auletta JJ, El Chaer F, Devine SM, Jimenez-Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Hourigan CS. Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia. JAMA Oncol 10(8):1104-1110, 2024. e-Pub 2024. PMID: 38696205.
- Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplant Cell Ther 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
- Senapati J, Jabbour E, Short NJ, Jain N, Haddad F, Bathala T, Kovalenko I, Bidikian A, Ravandi F, Khouri I, Kadia TM, Garris R, Montalban Bravo G, Chien K, Shpall E, Kebriaei P, Kantarjian HM. Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood Cancer J 14(1):129, 2024. e-Pub 2024. PMID: 39112504.
- Short NJ, Jabbour E, Nasr LF, Jain N, Haddad FG, Issa GC, Sasaki K, Senapati J, Kebriaei P, Garris R, Konopleva M, Ravandi F, Kantarjian H. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. Am J Hematol 99(7):1423-1426, 2024. e-Pub 2024. PMID: 38607091.
- Ramdial J, Kebriaei P, Champlin RE, Popat U, Rezvani K, Shpall EJ, Mehta RS. Improved survival with younger HLA-matched unrelated donors versus older matched sibling donor HCT with PTCy-prophylaxis. Leukemia 38(6):1432-1434, 2024. e-Pub 2024. PMID: 38698071.
- Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Kebriaei P, Aljawai Y, Khan HN, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J 14(1):82, 2024. e-Pub 2024. PMID: 38760362.
- Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, Rondon G, Kebriaei P, Champlin R, Daver N, Dinardo C, Short NJ, Shpall EJ, Oran B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 24(5):e196-e204, 2024. e-Pub 2024. PMID: 38403505.
- Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol 204(5):1944-1952, 2024. e-Pub 2024. PMID: 38448009.
- Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer 130(9):1663-1672, 2024. e-Pub 2024. PMID: 38127583.
- Jallouk AP, Kui N, Sun R, Westin JR, Steiner RE, Nair R, Nastoupil LJ, Fayad LE, Zaki AA, Hawkins M, Adkins S, Noorani M, Das K, Henderson J, Shpall EJ, Kebriaei P, Ramdial J, Flowers CR, Neelapu SS, Ahmed S, Strati P. Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy. Haematologica 109(5):1460-1468, 2024. e-Pub 2024. PMID: 38031807.
- Khouri IF, Alzahrani K, Kantarjian H, Milton DR, Gulbis AM, Sasaki K, Jain N, Short NJ, Kadia T, Daher M, Rafei H, Im JS, Marin D, Olson AL, Popat U, Qazilbash M, Ramdial J, Rondon G, Srour S, Kebriaei P, Shpall E, Champlin R, Jabbour EJ. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation. Am J Hematol 99(5):836-843, 2024. e-Pub 2024. PMID: 38400519.
- Ahmed S, Bashir Q, Bassett RL, Ullah F, Aung F, Valdez BC, Alousi AM, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Rezvani K, Mehta R, Shpall EJ, Ciurea S, Andersson BS, Champlin RE, Popat UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation. Am J Hematol 99(4):562-569, 2024. e-Pub 2024. PMID: 38314663.
- Marcoux C, Saliba RM, Wallis W, Khazal SJ, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin DC, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Adv 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
- Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson J, Banerjee P, Macapinlac HA, Ganesh C, Thall PF, Bassett R, Ammari M, Rao S, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil LJ, Flowers CR, Moseley SM, Lin P, Ang S, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall EJ, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors. Nat Med 30(3):772-784, 2024. e-Pub 2024. PMID: 38238616.
- Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplant Cell Ther 30(2):205.e1-205.e12, 2024. e-Pub 2024. PMID: 37437764.
- Saliba RM, Kanakry CG, Gadalla S, Kebriaei P, Rezvani K, Champlin RE, Shpall EJ, Weisdorf D, Mehta RS. Effect of donor age in patients with acute myeloid leukemia undergoing haploidentical hematopoietic cell transplantation vary by conditioning intensity and recipient age. Am J Hematol 99(1):38-47, 2024. e-Pub 2024. PMID: 37850688.
- Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J 13(1):68, 2023. e-Pub 2023. PMID: 37137874.
- Joseph J, Srour SA, Milton DR, Ramdial JL, Saini NY, Olson AL, Bashir Q, Oran B, Alousi AM, Hosing C, Qazilbash MH, Kebriaei P, Shpall EJ, Champlin RE, Popat UR. Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplant Cell Ther 29(12):770.e1-770.e6, 2023. e-Pub 2023. PMID: 37742746.
- Pasvolsky O, Bassett RL, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo KM, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EJ, Nieto Y. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC Cancer 23(1):1258, 2023. e-Pub 2023. PMID: 38124057.
- Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
- Kantarjian H, Haddad FG, Jain N, Sasaki K, Short NJ, Loghavi S, Kanagal-Shamanna R, Jorgensen J, Khouri I, Kebriaei P, Alvarado Y, Kadia T, Paul S, Garcia-Manero G, Dabaja B, Yilmaz M, Jacob J, Garris R, O'Brien S, Ravandi F, Jabbour E. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia. J Hematol Oncol 16(1):44, 2023. e-Pub 2023. PMID: 37131217.
- Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. Transplant Cell Ther 29(11):690-694, 2023. e-Pub 2023. PMID: 37607645.
- Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
- Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma. Am J Hematol 98(10):1571-1578, 2023. e-Pub 2023. PMID: 37461327.
- Abid MB, Estrada-Merly N, Zhang MJ, Chen K, Bredeson C, Allan D, Sabloff M, Marks DI, Litzow M, Hourigan C, Kebriaei P, Saber W. Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther 29(10):611-618, 2023. e-Pub 2023. PMID: 37481243.
- Abid MB, Estrada-Merly N, Zhang MJ, Chen K, Allan D, Bredeson C, Sabloff M, Guru Murthy GS, Badar T, Hashmi S, Aljurf M, Litzow MR, Kebriaei P, Hourigan CS, Saber W. Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia. Transplant Cell Ther 29(9):578.e1-578.e9, 2023. e-Pub 2023. PMID: 37406882.
- Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol 98(8):1196-1203, 2023. e-Pub 2023. PMID: 37183966.
- Pasvolsky, O, Marcoux, C, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Lee, HC, Patel, K, Kebriaei, P, Tewari, P, Crawford-Suber, L, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Outcomes of young adults (aged ≤ 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. British Journal of Haematology 202(4):866-873, 2023. e-Pub 2023. PMID: 37376789.
- He K, Hong DS, Ke D, Kebriaei P, Wang T, Danesi H, Bertolet G, Leuschner C, Puebla-Osorio N, Voss TA, Lin Q, Norry E, Fracasso PM, Welsh JW. Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy. Melanoma Res 33(4):332-337, 2023. e-Pub 2023. PMID: 37325860.
- Gui G, Dillon LW, Ravindra N, Hegde PS, Andrew G, Mukherjee D, Wong Z, Auletta J, Chaer FE, Chen E, Chen YB, Corner A, Devine SM, Iyer S, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Spellman SR, Zeger SL, Page KM, Hourigan CS. Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia. medRxiv, 2023. e-Pub 2023. PMID: 37577695.
- Tsimberidou AM, Guenther K, Andersson BS, Mendrzyk R, Alpert A, Wagner C, Nowak A, Aslan K, Satelli A, Richter F, Kuttruff-Coqui S, Schoor O, Fritsche J, Coughlin Z, Mohamed AS, Sieger K, Norris B, Ort R, Beck J, Vo HH, Hoffgaard F, Ruh M, Backert L, Wistuba II, Fuhrmann D, Ibrahim NK, Morris VK, Kee BK, Halperin DM, Nogueras-Gonzalez GM, Kebriaei P, Shpall EJ, Vining D, Hwu P, Singh H, Reinhardt C, Britten CM, Hilf N, Weinschenk T, Maurer D, Walter S. Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101). Cancer Immunol Res 11(7):925-945, 2023. e-Pub 2023. PMID: 37172100.
- Strati, P, Pasvolsky, O, Feng, L, Xu, G, Tewari, SO, Varghese, J, Ow, K, Santiago, M, Al Zaki, A, Jallouk, AP, Neelapu, SS, Kebriaei, P, Shpall, E, Ahmed, S. ASCT vs CART for patients with relapsed LBCL in PR. Blood Advances 7(11):2586-2589, 2023. e-Pub 2023. PMID: 36745104.
- Mehta, RS, Ramdial, JL, Marin, D, Alousi, AM, Kanakry, CG, Champlin, RE, Rezvani, K, Shpall, E, Page, KM, Gadalla, SM, Kebriaei, P, Weisdorf, DJ. Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. Transplantation and Cellular Therapy 29(6):377.e1-377.e7, 2023. e-Pub 2023. PMID: 36990221.
- Marcoux C, Marin D, Ramdial J, AlAtrash G, Alousi AM, Oran B, Kebriaei P, Popat UR, Rezvani K, Champlin RE, Shpall EJ, Mehta RS. Younger haploidentical donor versus older matched unrelated donor for patients with AML/MDS. Am J Hematol 98(5):712-719, 2023. e-Pub 2023. PMID: 36734029.
- Wang XS, Srour SA, Mendoza T, Whisenant M, Subbiah I, Gonzalez E, Kamal M, Shen SE, Cleeland C, Kebriaei P, Rezvani K, Neelapu S, Ahmed S, Shpall E. Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. Br J Haematol 201(4):738-746, 2023. e-Pub 2023. PMID: 36733986.
- Boyiadzis, M, Zhang, MJ, Chen, K, Abdel-Azim, H, Abid, MB, Aljurf, M, Bacher, U, Badar, T, Badawy, SM, Battiwalla, M, Bejanyan, N, Bhatt, VR, Brown, VI, Castillo, P, Cerny, J, Copelan, E, Craddock, C, Dholaria, B, Perez, MA, Ebens, CL, Gale, RP, Ganguly, S, Gowda, L, Grunwald, MR, Hashmi, SK, Hildebrandt, G, Iqbal, M, Jamy, O, Kharfan-Dabaja, MA, Khera, N, Lazarus, HM, Lin, RJ, Modi, D, Nathan, S, Nishihori, T, Patel, SS, Pawarode, A, Saber, W, Sharma, A, Solh, MM, Wagner, JL, Wang, TP, Williams, KM, Winestone, LE, Wirk, B, Zeidan, AM, Hourigan, CS, Litzow, M, Kebriaei, P, De Lima, M, Page, KM, Weisdorf, DJ. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes. Leukemia 37(5):1006-1017, 2023. e-Pub 2023. PMID: 36310182.
- Senapati J, Jabbour E, Konopleva M, Short NJ, Tang G, Daver N, Kebriaei P, Kadia T, Pemmaraju N, Takahashi K, DiNardo C, Sasaki K, Borthakur G, Thakral B, Kanagal-Shamanna R, Patel K, Ravandi F, Roberts K, Mullighan C, Kantarjian H, Jain N. Philadelphia-Like Genetic Rearrangements in Adults With B-Cell ALL: Refractoriness to Chemotherapy and Response to Tyrosine Kinase Inhibitor in ABL Class Rearrangements. JCO Precis Oncol 7:e2200707, 2023. e-Pub 2023. PMID: 37196217.
- Mehta RS, Marin D, Alousi A, Kanakry CG, Champlin RE, Rezvani K, Shpall EJ, Page K, Gadalla SM, Weisdorf D, Kebriaei P. Haploidentical vs matched unrelated donors for patients with ALL. Blood Adv 7(8):1594-1603, 2023. e-Pub 2023. PMID: 36630564.
- Nikiforow S, Frigault MJ, Frey NV, Gardner RA, Komanduri KV, Perales MA, Kebriaei P, Warkentin PI, Pasquini M, Aho JL, Levine BL, Heslop HE, Hlucky TL, Habucky K, Gharibo M, Jagasia M, Locke FL. Paving the Road for Chimeric Antigen Receptor T Cells. Transplant Cell Ther 29(4):228-239, 2023. e-Pub 2023. PMID: 36709800.
- Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
- Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14). Transplant Cell Ther 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
- Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, Mukherjee D, Zeger SL, El Chaer F, Spellman S, Howard A, Chen K, Auletta J, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Weisdorf DJ, Hourigan CS. DNA Sequencing to Detect Residual Disease in Adults with Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. JAMA 329(9):745-755, 2023. e-Pub 2023. PMID: 36881031.
- Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2023. PMID: 36470579.
- Kantarjian H, Short NJ, Jain N, Sasaki K, Huang X, Haddad FG, Khouri I, DiNardo CD, Pemmaraju N, Wierda W, Garcia-Manero G, Kebriaei P, Garris R, Loghavi S, Jorgensen J, Kwari M, O'Brien S, Ravandi F, Jabbour E. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol 98(3):493-501, 2023. e-Pub 2023. PMID: 36600670.
- Ngo-Huang A, Ombres R, Saliba RM, Szewczyk N, Adekoya L, Soones TN, Ferguson J, Fontillas RC, Gulbis AM, Hosing C, Kebriaei P, Lindsay R, Marin DC, Mehta RS, Alousi AM, Srour S, Oran B, Olson AL, Qazilbash MH, Rivera Z, Champlin RE, Shpall EJ, Popat UR. Enhanced Recovery Stem-Cell Transplantation. JCO Oncol Pract 19(3):E417-E427, 2023. e-Pub 2023. PMID: 36626702.
- Nieto Y, Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C, Sr S, Ramdial J, Mahadeo K, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall E. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq, 2023. e-Pub 2023. PMID: 36798261.
- Hong, DS, Van Tine, BA, Biswas, S, McAlpine, C, Johnson, M, Olszanski, AJ, Clarke, JM, Araujo, DM, Blumenschein, GR, Kebriaei, P, Lin, Q, Tipping, AJ, Sanderson, JP, Wang, R, Trivedi, T, Annareddy, T, Bai, J, Rafail, S, Sun, A, Fernandes, L, Navenot, JM, Bushman, F, Everett, JK, Karadeniz, D, Broad, R, Isabelle, M, Naidoo, R, Bath, N, Betts, G, Wolchinsky, Z, Batrakou, D, Van Winkle, E, Elefant, E, Ghobadi, A, Cashen, A, Grand’Maison, A, McCarthy, P, Fracasso, PM, Norry, E, Williams, D, Druta, M, Liebner, DA, Odunsi, K, Butler, M. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients. Nature medicine 29(1):104-114, 2023. e-Pub 2023. PMID: 36624315.
- Murthy HS, Zhang MJ, Chen K, Ahmed S, Deotare U, Ganguly S, Kansagra A, Michelis FV, Nishihori T, Patnaik M, Abid MB, Aljurf M, Arai Y, Bacher U, Badar T, Badawy SM, Ballen K, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Brown VI, Martino R, Cahn JY, Castillo P, Cerny J, Chhabra S, Copelan E, Daly A, Dholaria B, Diaz Perez MA, Freytes CO, Grunwald MR, Hashmi S, Hildebrandt GC, Jamy O, Joseph J, Kanakry CG, Khera N, Krem MM, Kuwatsuka Y, Lazarus HM, Lekakis LJ, Liu H, Modi D, Munshi PN, Mussetti A, Palmisiano N, Patel SS, Rizzieri DA, Seo S, Shah MV, Sharma A, Sohl M, Solomon SR, Ulrickson M, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wang T, Wirk B, Zeidan A, Litzow M, Kebriaei P, Hourigan CS, Weisdorf DJ, Saber W, Kharfan-Dabaja MA. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm. Blood Adv 7(22):7007-7016, 2023. e-Pub 2023. PMID: 37792849.
- Strati P, Jallouk A, Deng Q, Li X, Feng L, Sun R, Adkins S, Johncy S, Cain T, Steiner RE, Ahmed S, Chihara D, Fayad LE, Iyer SP, Horowitz S, Nastoupil LJ, Nair R, Hassan A, Daoud TE, Hawkins M, Rodriguez MA, Shpall EJ, Ramdial JL, Kebriaei P, Hong DS, Westin JR, Neelapu SS, Green MR. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv 7(21):6785-6789, 2023. e-Pub 2023. PMID: 37389847.
- Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
- Ghobadi A, Slade M, Kantarjian H, Alvarenga J, Aldoss I, Mohammed KA, Jabbour E, Faramand R, Shah B, Locke F, Fingrut W, Park JH, Short NJ, Gao F, Uy GL, Westervelt P, DiPersio JF, Champlin RE, Al Malki MM, Ravandi F, Kebriaei P. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission. Blood 140(20):2101-2112, 2022. e-Pub 2022. PMID: 35877996.
- Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med 3(11), 2022. e-Pub 2022. PMID: 36384092.
- Singh H, Srour SA, Milton DR, McCarty J, Dai C, Gaballa MR, Ammari M, Olivares S, Huls H, De Groot E, Marin D, Petropoulos D, Olson AL, Anderlini P, Im JS, Khouri I, Hosing CM, Rezvani K, Champlin RE, Shpall EJ, Cooper LJN, Kebriaei P. Sleeping beauty generated CD19 CAR T-Cell therapy for advanced B-Cell hematological malignancies. Front Immunol 13, 2022. e-Pub 2022. PMID: 36439104.
- Benjamin, R, Jain, N, Maus, MV, Boissel, N, Graham, C, Jozwik, A, Yallop, D, Konopleva, M, Frigault, M, Teshima, T, Kato, K, Boucaud, F, Balandraud, S, Gianella-Borradori, A, Binlich, F, Marchiq, I, Dupouy, S, Almena-Carrasco, M, Pannaux, M, Fouliard, S, Brissot, E, Mohty, M, Bonganay, L, Catt, L, Chappell, J, Cheung, G, Chu, V, Cuthill, K, Devereux, S, Dunlop, A, Ellard, R, Farzeneh, F, Folarin, N, Giemza, E, Kassam, S, Kazmi, M, Kuhnl, A, Lewis, J, Liskova, M, Mason, A, Metaxa, V, Mufti, G, Munro, H, Pagliuca, A, Patten, P, Potter, V, Jabbour, EJ, Kantarjian, HM, Kebriaei, P, Wierda, WG. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM). The Lancet Haematology 9(11):e833-e843, 2022. e-Pub 2022. PMID: 36228643.
- Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
- Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
- Pasvolsky, O, Milton, D, Rauf, M, Ghanem, S, Masood, A, Mohamedi, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Lin, P, Qazilbash, MH. MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia 22:S421-S422, 2022. e-Pub 2022. PMID: 36164172.
- Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide Versus Tacrolimus and Methotrexate Graft-Versus-Host Disease Prophylaxis for HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
- Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene Ciloleucel Therapy of Large B-Cell Lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
- Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
- Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan ± clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant 57(8):1295-1303, 2022. e-Pub 2022. PMID: 35610308.
- Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Kebriaei P. Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
- Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv 6(13):4006-4014, 2022. e-Pub 2022. PMID: 35533262.
- Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
- Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
- Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
- Maakaron JE, Zhang MJ, Chen K, Abhyankar S, Bhatt VR, Chhabra S, El Jurdi N, Farag SS, He F, Juckett M, de Lima M, Majhail N, van der Poel M, Saad A, Savani B, Ustun C, Waller EK, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D. Age is no barrier for adults undergoing HCT for AML in CR1. Bone Marrow Transplant 57(6):911-917, 2022. e-Pub 2022. PMID: 35368040.
- Short NJ, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. Am J Hematol 97(6):E201-E204, 2022. e-Pub 2022. PMID: 35266566.
- Li A, Martens KL, Nguyen D, Basom R, Rondon G, Jin S, Young E, Amos CI, Lee SJ, Davis C, Garcia DA, Champlin R, Shpall E, Kebriaei P, Rojas Hernandez C. External validation of the HIGH-2-LOW model. Am J Hematol 97(6):740-748, 2022. e-Pub 2022. PMID: 35266218.
- Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Adv 6(9):2867-2871, 2022. e-Pub 2022. PMID: 35015825.
- Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy. Haematologica 107(4):899-908, 2022. e-Pub 2022. PMID: 33951890.
- Gaballa MR, Banerjee PP, Milton DR, Jiang X, Ganesh C, Khazal SJ, Nandivada V, Islam S, Kaplan M, Daher M, Basar R, Alousi A, Mehta RS, Alatrash G, Khouri IF, Oran B, Marin D, Popat UR, Olson AL, Tewari P, Jain N, Jabbour EJ, Ravandi F, Kantarjian HM, Chen K, Champlin RE, Shpall EJ, Rezvani K, Kebriaei P. Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. Blood 139(12):1908-1919, 2022. e-Pub 2022. PMID: 34914826.
- Hong, DS, Butler, M, Pachynski, RK, Sullivan, RJ, Kebriaei, P, Boross-Harmer, S, Ghobadi, A, Frigault, M, Ileana Dumbrava, EE, Sauer, A, Brophy, F, Navenot, JM, Fayngerts, S, Wolchinsky, Z, Broad, R, Batrakou, D, Wang, R, Solis Soto, LM, Duose, D, Sanderson, JP, Gerry, A, Marks, D, Bai, J, Norry, E, Fracasso, PM. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Frontiers in Oncology 12, 2022. e-Pub 2022. PMID: 35372008.
- Ombres R, des Bordes JKA, Popat UR, Yennu S, Champlin RE, Mohile SG, Kebriaei P, Holmes HM. Serial frailty assessments following allogeneic stem cell transplant in older adults. J Geriatr Oncol 13(2):194-199, 2022. e-Pub 2022. PMID: 34493481.
- Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv 6(3):828-847, 2022. e-Pub 2022. PMID: 34551064.
- Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada-Merly N, Marks DI, Al-Homsi AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan-Dabaja MA, Lazarus HM, Ganguly S, Bredeson C, Diaz Perez MA, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, Bashey A, Murthy HS, Yared JA, Aldoss I, Farhadfar N, Liu H, Abdel-Azim H, Waller EK, Solh M, Seftel MD, van der Poel M, Grunwald MR, Liesveld JL, Kamble RT, McGuirk J, Munker R, Cahn JY, Lee JW, Freytes CO, Krem MM, Winestone LE, Gergis U, Nathan S, Olsson RF, Verdonck LF, Sharma A, Ringdén O, Friend BD, Cerny J, Choe H, Chhabra S, Nishihori T, Seo S, George B, Baxter-Lowe LA, Hildebrandt GC, de Lima M, Litzow M, Kebriaei P, Hourigan CS, Abid MB, Weisdorf DJ, Saber W. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Adv 6(1):339-357, 2022. e-Pub 2022. PMID: 34547770.
- Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):710-721, 2022. e-Pub 2022. PMID: 34686083.
- Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2022. PMID: 34629467.
- Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
- Whisenant MS, Srour SA, Williams LA, Subbiah I, Griffin D, Ponce D, Kebriaei P, Neelapu SS, Shpall E, Ahmed S, Wang XS. The Unique Symptom Burden of Patients Receiving CAR T-Cell Therapy. Semin Oncol Nurs 37(6), 2021. e-Pub 2021. PMID: 34629213.
- Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. Bone Marrow Transplant 56(12):3068-3077, 2021. e-Pub 2021. PMID: 34584240.
- Khazal S, Kebriaei P. Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes. Leuk Lymphoma 62(12):1-14, 2021. e-Pub 2021. PMID: 34080951.
- Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
- Metheny L, Callander NS, Hall AC, Zhang MJ, Bo-Subait K, Wang HL, Agrawal V, Al-Homsi AS, Assal A, Bacher U, Beitinjaneh A, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Cairo M, Cerny J, DeFilipp Z, Perez MAD, Freytes CO, Ganguly S, Grunwald MR, Hashmi S, Hildebrandt GC, Inamoto Y, Kanakry CG, Kharfan-Dabaja MA, Lazarus HM, Lee JW, Nathan S, Nishihori T, Olsson RF, Ringdén O, Rizzieri D, Savani BN, Savoie ML, Seo S, van der Poel M, Verdonck LF, Wagner JL, Yared JA, Hourigan CS, Kebriaei P, Litzow M, Sandmaier BM, Saber W, Weisdorf D, de Lima M. Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplant Cell Ther 27(11):923.e1-923.e12, 2021. e-Pub 2021. PMID: 34428556.
- Wang XS, Srour SA, Whisenant M, Subbiah IM, Chen TH, Ponce D, Gonzalez AG, Kamal M, Mendoza T, Cleland CS, Kebriaei P, Neelapu SS, Rezvani K, Ahmed S, Shpall E. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies. Transplant Cell Ther 27(11):930.e1-930.e10, 2021. e-Pub 2021. PMID: 34265479.
- Strati P, Varma A, Adkins S, Nastoupil LJ, Westin J, Hagemeister FB, Fowler NH, Lee HJ, Fayad LE, Samaniego F, Ahmed S, Chen Y, Horowitz S, Arafat S, Johncy S, Kebriaei P, Mulanovich VE, Ariza Heredia E, Neelapu SS. Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma. Haematologica 106(10):2667-2672, 2021. e-Pub 2021. PMID: 32732355.
- Sasaki K, Kantarjian HM, Morita K, Short NJ, Konopleva M, Jain N, Ravandi F, Garcia-Manero G, Wang S, Khoury JD, Jorgensen JL, Champlin RE, Khouri IF, Kebriaei P, Schroeder HM, Khouri M, Garris R, Takahashi K, O'Brien SM, Jabbour EJ. Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia. Cancer 127(18):3381-3389, 2021. e-Pub 2021. PMID: 34138471.
- Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM. Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56(9):2108-2117, 2021. e-Pub 2021. PMID: 33864019.
- Martens KL, Amos CI, Hernandez CR, Kebriaei P, da Costa WL, Basom R, Davis C, Kesten M, Carrier M, Garcia DA, Lee SJ, Li A. Impact of anticoagulation on recurrent thrombosis and bleeding after hematopoietic cell transplantation. Am J Hematol 96(9):1137-1146, 2021. e-Pub 2021. PMID: 34097772.
- Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):2710-2719, 2021. e-Pub 2021. PMID: 33929874.
- Jain N, Maiti A, Ravandi F, Konopleva M, Daver N, Kadia T, Pemmaraju N, Short N, Kebriaei P, Ning J, Cortes J, Jabbour E, Kantarjian H. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol 96(8):1000-1007, 2021. e-Pub 2021. PMID: 33991360.
- Yalniz FF, Saliba RM, Greenbaum U, Ramdial J, Popat U, Oran B, Alousi A, Olson A, Alatrash G, Marin D, Rezvani K, Hosing C, Im J, Mehta R, Qazilbash M, Joseph JJ, Rondon G, Kanagal-Shamanna R, Shpall E, Champlin R, Kebriaei P. Outcomes of Second Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myeloid Leukemia. Transplant Cell Ther 27(8):689-695, 2021. e-Pub 2021. PMID: 34023569.
- Sasaki K, Kantarjian HM, Short NJ, Samra B, Khoury JD, Kanagal Shamanna R, Konopleva M, Jain N, DiNardo CD, Khouri R, Garcia-Manero G, Kadia TM, Wierda WG, Khouri IF, Kebriaei P, Mehta RS, Champlin RE, Garris R, Cheung CM, Daver N, Thompson PA, Yilmaz M, Ravandi F, Jabbour E. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 127(15):2648-2656, 2021. e-Pub 2021. PMID: 33793964.
- Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. Bone Marrow Transplant 56(8):2005-2012, 2021. e-Pub 2021. PMID: 33846563.
- Olson A, Lin R, Marin D, Rafei H, Bdiwi MH, Thall PF, Basar R, Abudayyeh A, M, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K, MD, PhD. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. American Society of Clinical Oncology (ASCO) 39(24):2710-2720, 2021. e-Pub 2021.
- Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
- Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D. Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission. Leukemia 35(7):2076-2085, 2021. e-Pub 2021. PMID: 33785862.
- Jabbour E, Sasaki K, Short NJ, Ravandi F, Huang X, Khoury JD, Kanagal-Shamanna R, Jorgensen J, Khouri IF, Kebriaei P, Jain N, Alvarado Y, Kadia TM, Paul S, Garcia-Manero G, Dabaja BS, Burger JA, DiNardo CD, Daver NA, Montalban-Bravo G, Yilmaz M, Ohanian M, Ferrajoli A, Jacob J, Rostykus M, Garris R, O'Brien S, Kantarjian HM. Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia. Cancer 127(12):2025-2038, 2021. e-Pub 2021. PMID: 33740268.
- Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
- Mehta RS, Bassett R, Rondon G, Overman BJ, Popat UR, Hosing CM, Rezvani K, Qazilbash MH, Anderlini P, Jones RB, Kebriaei P, Marin D, Khouri IF, Oran B, Ciurea SO, Kondo K, Couriel DR, Shpall EJ, Champlin RE, Alousi AM. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant 56(6):1316-1324, 2021. e-Pub 2021. PMID: 33398094.
- Oran B, Saliba RM, Mehta RS, Alousi AM, Marin D, Valdez BC, Chen J, Bashir Q, Ciurea SO, Olson AL, Hosing C, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Andersson BS, Popat UR. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 127(10):1598-1605, 2021. e-Pub 2021. PMID: 33471943.
- Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
- Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia. Transplant Cell Ther 27(5):430.e1-430.e7, 2021. e-Pub 2021. PMID: 33965187.
- Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
- Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther 27(3):272.e1-272.e5, 2021. e-Pub 2021. PMID: 33781539.
- Ragoonanan D, Khazal SJ, Wang J, Payne A, Kohorst M, Harden A, Tewari P, Petropoulos D, Shoberu B, Kebriaei P, Mahadeo KM, Tambaro FP. Improved detection of sinusoidal obstructive syndrome using pediatric–AYA diagnostic criteria and severity grading. Bone Marrow Transplant 56(1):175-184, 2021. e-Pub 2021. PMID: 32665674.
- Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 144(1):74-81, 2021. e-Pub 2021. PMID: 32604096.
- Bejanyan N, Zhang M, Bo-Subait K, Brunstein C, Wang H, Warlick ED, Giralt S, Nishihori T, Martino R, Passweg J, Dias A, Copelan E, Hale G, Gale RP, Solh M, Kharfan-Dabaja MA, Diaz MA, Ganguly S, Gore S, Verdonck LF, Hossain NM, Kekre N, Savani B, Byrne M, Kanakry C, Cairo MS, Ciurea S, Schouten HC, Bredeson C, Munker R, Lazarus H, Cahn JY, van Der Poel M, Rizzieri D, Yared JA, Freytes C, Cerny J, Aljurf M, Palmisiano ND, Pawarode A, Bacher VU, Grunwald MR, Nathan S, Wirk B, Hildebrandt GC, Seo S, Olsson RF, George B, de Lima M, Hourigan CS, Sandmaier BM, Litzow M, Kebriaei P, Saber W, Weisdorf D. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant 27(1):68.e1-68.e9, 2021. e-Pub 2020. PMID: 33010430.
- Kebriaei P. Toward a cure in relapsed ALL: we must do better. Leuk Lymphoma 61(11):1-2, 2020. e-Pub 2020. PMID: 32779948.
- Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood 136(15):1786-1789, 2020. e-Pub 2020. PMID: 32492706.
- Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
- Tambaro FP, Khazal S, Nunez C, Ragoonanan D, Tewari P, Petropoulos D, Kebriaei P, Wierda WG, Mahadeo KM. Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD-19 chimeric antigen receptor T-cell therapy. Clin Case Rep 8(9):1678-1681, 2020. e-Pub 2020. PMID: 32983475.
- Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
- Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(16):3943-3951, 2020. e-Pub 2020. PMID: 32822484.
- Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv 4(13):3180-3190, 2020. e-Pub 2020. PMID: 32663298.
- Strati P, Ahmed S, Kebriaei P, Nastoupil LJ, Claussen CM, Watson G, Horowitz SB, Brown ART, Do B, Rodriguez MA, Nair R, Shpall EJ, Green MR, Neelapu SS, Westin JR. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv 4(13):3123-3127, 2020. e-Pub 2020. PMID: 32645136.
- Jabbour E, Richard-Carpentier G, Sasaki Y, Konopleva M, Patel K, Roberts K, Gu Z, Wang F, Huang X, Sasaki K, Short NJ, Jain N, Ravandi F, Daver NG, Kadia TM, Alvarado Y, DiNardo CD, Issa GC, Pemmaraju N, Garcia-Manero G, Verstovsek S, Wang S, Khoury JD, Jorgensen J, Champlin R, Khouri I, Kebriaei P, Schroeder H, Khouri M, Mullighan CG, Takahashi K, O'Brien SM, Kantarjian H. Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematol 7(7):e523-e533, 2020. e-Pub 2020. PMID: 32589978.
- Srour SA, Kongtim P, Rondon G, Chen J, Petropoulos D, Ramdial J, Popat U, Kebriaei P, Qazilbash M, Shpall EJ, Champlin RE, Ciurea SO. Haploidentical Transplants for Patients with Relapse After the First Allograft. Am J Hematol. e-Pub 2020. PMID: 32619033.
- Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(6):1077-1083, 2020. e-Pub 2020. PMID: 31786242.
- Kongtim P, Bittencourt M, Srour SA, Ramdial J, Rondon G, Chen J, Khouri I, Betul O, Popat U, Olson A, Bashir Q, Shpall EJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical Transplants for Patients with Graft Failure After the First Allograft. Am J Hematol. e-Pub 2020. PMID: 32602112.
- Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Malki MA, Munker R, Rizzieri D, Khera N, Nakamura R, Ringdén O, van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolaños-Meade J, Elsawy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Caro PC, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, De Lima M, Litzow M, Bachanova V, Weisdorf D, the CIBMTR ALCO. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. Haematologica 105(5):1329-1338, 2020. e-Pub 2020. PMID: 31558669.
- Kebriaei P, Hayes J, Daly A, Uberti J, Marks DI, Soiffer R, Waller EK, Burke E, Skerrett D, Shpall E, Martin PJ. A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 26(5):835-844, 2020. e-Pub 2020. PMID: 31505228.
- Al Malki MM, Yang D, Labopin M, Afanasyev B, Angelucci E, Bashey A, Socié G, Karduss-Urueta A, Helbig G, Bornhauser M, Niittyvuopio R, Ganser A, Ciceri F, Brecht A, Koc Y, Bejanyan N, Ferraro F, Kebriaei P, Mokhtari S, Ghobadi A, Nakamura R, Forman SJ, Champlin R, Mohty M, Ciurea SO, Nagler A. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation. Blood Adv 4(9):2073-2083, 2020. e-Pub 2020. PMID: 32396617.
- Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma With Chromosome 1q Gain and 1p Deletion After Autologous Hematopoietic Stem Cell Transplantation: propensity-score matched analysis: Outcome of 1q+/1p- MM pts after auto-HCT. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
- Richard-Carpentier G, Jabbour E, Short NJ, Rausch CR, Savoy JM, Bose P, Yilmaz M, Jain N, Borthakur G, Ohanian M, Alvarado Y, Rytting M, Kebriaei P, Konopleva M, Kantarjian H, Ravandi F. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(4):212-218, 2020. e-Pub 2020. PMID: 32035785.
- Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
- Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty generated CD19specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
- Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
- Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SO. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 26(1):197-203, 2020. e-Pub 2020. PMID: 31518645.
- Srour SA, Saliba RM, Bittencourt MCB, Perez JMR, Kongtim P, Alousi A, Al-Atrash G, Olson A, Betul O, Mehta R, Popat U, Hosing C, Bashir Q, Khouri I, Kebriaei P, Masarova L, Short N, Jabbour E, Daver N, Konopleva M, Ravandi F, Kantarjian H, Champlin RE, Ciurea SO. Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation. Am J Hematol 94(12):1382-1387, 2019. e-Pub 2019. PMID: 31595538.
- Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica 104(12):e555-e557, 2019. e-Pub 2019. PMID: 30948491.
- Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma 60(14):1-8, 2019. e-Pub 2019. PMID: 31282244.
- Abou Dalle I, Kantarjian HM, Short NJ, Konopleva M, Jain N, Garcia-Manero G, Garris R, Qiao W, Cortes JE, O'Brien S, Kebriaei P, Kadia T, Jabbour E, Ravandi F. Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors. Am J Hematol 94(12):1388-1395, 2019. e-Pub 2019. PMID: 31595534.
- Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplant 54(11):1868-1880, 2019. e-Pub 2019. PMID: 31092900.
- Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of autologous transplantation in multiple myeloma patients with t(11;14): a propensity-score matched analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
- Marks DI, Kebriaei P, Stelljes M, Gökbuget N, Kantarjian H, Advani AS, Merchant A, Stock W, Cassaday RD, Wang T, Zhang H, Loberiza F, Vandendries E, DeAngelo DJ. Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 25(9):1720-1729, 2019. e-Pub 2019. PMID: 31039409.
- Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98(9):2233-2235, 2019. e-Pub 2019. PMID: 31243571.
- Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Oran B, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
- Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 54(6):839-848, 2019. e-Pub 2019. PMID: 30258129.
- Ghobadi A, Milton DR, Gowda L, Rondon G, Chemaly RF, Hamdi A, Alousi A, Afrough A, Oran B, Ciurea S, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Champlin RE, Bashir Q. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med 67(2):51-55, 2019. e-Pub 2019. PMID: 30683577.
- Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
- Maymani H, Lin P, Saliba RM, Popat U, Bashir Q, Shah N, Patel K, Parmar S, Kebriaei P, Hosing C, Ciurea S, Andersson B, Shpall E, Champlin R, Srour SA, Qazilbash MH. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant 25(5):1039-1044, 2019. e-Pub 2019. PMID: 30639822.
- Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol 94(3):E72-E74, 2019. e-Pub 2019. PMID: 30548467.
- Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94(1):E2-E5, 2019. e-Pub 2019. PMID: 30300461.
- Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. e-Pub 2018. PMID: 30576834.
- Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. e-Pub 2018. PMID: 30389035.
- Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. Biol Blood Marrow Transplant. e-Pub 2018. PMID: 30308325.
- Jabbour E, Sasaki K, Ravandi F, Huang X, Short NJ, Khouri M, Kebriaei P, Burger J, Khoury J, Jorgensen J, Jain N, Konopleva M, Garcia-Manero G, Kadia T, Cortes J, Jacob J, Montalbano K, Garris R, O'Brien S, Kantarjian HM. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer 124(20):4044-4055, 2018. e-Pub 2018. PMID: 30307611.
- Shah MV, Saliba RM, Rondon G, Chen J, Soebbing D, Rus I, Alousi A, Oran B, Kebriaei P, Qazilbash M, Parmar S, Hosing C, Khouri IF, Popat UR, Champlin RE, Ciurea SO. Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation. Bone Marrow Transplant. e-Pub 2018. PMID: 30337700.
- Ciurea SO, Bittencourt MCB, Milton DR, Cao K, Kongtim P, Rondon G, Chen J, Konopleva M, Perez JMR, El Shazly MF, Aljadayeh M, Alvarez M, Im J, Al-Atrash G, Mehta R, Popat U, Bashir Q, Oran B, Hosing CM, Khouri IF, Kebriaei P, Champlin RE. Is a matched unrelated donor search needed for all allogeneic transplant candidates?. Blood Adv 2(17):2254-2261, 2018. e-Pub 2018. PMID: 30206098.
- Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant 24(8):1602-1609, 2018. e-Pub 2018. PMID: 29501779.
- Mah A, Viola GM, Ariza Heredia E, Rezvani K, Kebriaei P, Bhatti MM, Han X, Shpall EJ, Mulanovich VE. Graft loss attributed to possible transfusion-transmitted ehrlichiosis following cord blood stem cell transplant. Transpl Infect Dis 20(4):e12899, 2018. e-Pub 2018. PMID: 29668040.
- Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran B. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant 24(7):1514-1520, 2018. e-Pub 2018. PMID: 29448058.
- Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin RE. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood 131(26):2989-2992, 2018. e-Pub 2018. PMID: 29769261.
- Ciurea SO, Shah MV, Saliba RM, Gaballa S, Kongtim P, Rondon G, Chen J, Wallis W, Cao K, Konopleva M, Daver N, Cortes J, Ravandi F, Alousi A, Ahmed S, Popat U, Parmar S, Bashir Q, Betul O, Hosing C, Shpall EJ, Rezvani K, Khouri IF, Kebriaei P, Champlin RE. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 24(6):1232-1236, 2018. e-Pub 2018. PMID: 28918304.
- Bejanyan N, Zhang MJ, Wang HL, Lazaryan A, de Lima M, Marks DI, Sandmaier BM, Bachanova V, Rowe J, Tallman M, Kebriaei P, Kharfan-Dabaja M, Peter Gale R, Lazarus HM, Ustun C, Copelan E, Ky Hamilton B, Schiller G, Hogan W, Hashmi S, Seftel M, Kanakry CG, Olsson RF, Martino R, Saber W, Khoury HJ, Weisdorf DJ. Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. Biol Blood Marrow Transplant 24(5):945-955, 2018. e-Pub 2018. PMID: 29275139.
- Kebriaei P, Cutler C, de Lima M, Giralt S, Lee SJ, Marks D, Merchant A, Stock W, van Besien K, Stelljes M. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant 53(4):449-456, 2018. e-Pub 2018. PMID: 29330398.
- Neelapu SS, Tummala S, Kebriaei P, Wierda W, Locke FL, Lin Y, Jain N, Daver N, Gulbis AM, Adkins S, Rezvani K, Hwu P, Shpall EJ. Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15(4):218, 2018. e-Pub 2018. PMID: 29434334.
- Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, Horowitz MM, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI, the CIBMTR ALCO. Intravenous Busulfan Compared to Total Body Irradiation Pre-Transplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 24(4):726-733, 2018. e-Pub 2018. PMID: 29197676.
- Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2018. PMID: 29269797.
- Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
- Jabbour E, Ravandi F, Kebriaei P, Huang X, Short NJ, Thomas D, Sasaki K, Rytting M, Jain N, Konopleva M, Garcia-Manero G, Champlin R, Marin D, Kadia T, Cortes J, Estrov Z, Takahashi K, Patel Y, Khouri MR, Jacob J, Garris R, O'Brien S, Kantarjian H. Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA Oncol 4(2):230-234, 2018. e-Pub 2018. PMID: 28859185.
- Abaza Y, M Kantarjian H, Faderl S, Jabbour E, Jain N, Thomas D, Kadia T, Borthakur G, D Khoury J, Burger J, Wierda W, O'Brien S, Konopleva M, Ferrajoli A, Kebriaei P, Dabaja B, Kornblau S, Alvarado Y, Daver N, Pemmaraju N, Bose P, Thompson P, Al Azzawi H, Kelly M, Garris R, Jain P, Garcia-Manero G, Cortes J, Ravandi F. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. Am J Hematol 93(1):91-99, 2018. e-Pub 2018. PMID: 29047158.
- Jain N, Lu X, Daver N, Thakral B, Wang SA, Konoplev S, Patel K, Kanagal-Shamanna R, Valentine M, Tang G, Pemmaraju N, Jorgensen J, Kebriaei P, Nunez CA, Wierda W, Jabbour E, Roberts KG, Mullighan CG, Kantarjian H, Konopleva M. Concurrent diagnosis of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients. Haematologica 102(12):e514-e517, 2017. e-Pub 2017. PMID: 28860345.
- Rondón G, Saliba RM, Chen J, Ledesma C, Alousi AM, Oran B, Hosing CM, Kebriaei P, Khouri IF, Shpall EJ, Popat UR, Champlin RE, Ciurea SO. Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem-Cell Transplant Outcomes. Biol Blood Marrow Transplant 23(12):2166-2171, 2017. e-Pub 2017. PMID: 28844946.
- Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. Histologic Grade 1 is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol 41(11):1483-1490, 2017. e-Pub 2017. PMID: 28834808.
- Maher OM, Silva JG, Huh WW, Cuglievan B, DePombo A, Kebriaei P, Park M, Liu D, Tillman C, Tarek N, Cooper LJN, Tewari P. Etiologies and Impact of Readmission Rates in the First 180 Days After Hematopoietic Stem Cell Transplantation in Children, Adolescents, and Young Adults. J Pediatr Hematol Oncol 39(8):609-613, 2017. e-Pub 2017. PMID: 28859043.
- Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer 123(18):3568-3575, 2017. e-Pub 2017. PMID: 28513828.
- Mehta RS, Saliba RM, Cao K, Kaur I, Rezvani K, Chen J, Olson A, Parmar S, Shah N, Marin D, Alousi A, Hosing C, Popat U, Kebriaei P, Champlin R, de Lima M, Skerrett D, Burke E, Shpall EJ, Oran B. Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens Improves Time to Neutrophil Recovery. Biol Blood Marrow Transplant 23(8):1359-1366, 2017. e-Pub 2017. PMID: 28506845.
- Kantarjian HM, DeAngelo DJ, Advani AS, Stelljes M, Kebriaei P, Cassaday RD, Merchant AA, Fujishima N, Uchida T, Calbacho M, Ejduk AA, O'Brien SM, Jabbour EJ, Zhang H, Sleight BJ, Vandendries ER, Marks DI. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol 4(8):e387-e398, 2017. e-Pub 2017. PMID: 28687420.
- Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol 178(4):561-570, 2017. e-Pub 2017. PMID: 28485023.
- Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogenic stem cell transplantation using reduced intensity conditioning. Cancer 123(14):2661-2670, 2017. e-Pub 2017. PMID: 28324640.
- Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors. Leukemia 31(7):1654-1657, 2017. e-Pub 2017. PMID: 28400618.
- Bachegowda LS, Saliba RM, Ramlal R, Kongtim P, Chen J, Rondon G, Wallis W, Alousi A, Ahmed S, Hosing CM, Parmar S, Qazilbash M, Khouri IF, Bashir Q, Oran B, Popat U, Shpall EJ, Marin D, Rezvani K, Kebriaei P, Champlin RE, Ciurea SO. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood 129(22):3031-3033, 2017. e-Pub 2017. PMID: 28351938.
- Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W, International Blood ALWCOTCF, Research MT, Match Registry ACBTNMDPT, theMedicalCollegeofWisconsin. Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. Cancer 123(11):2035-2042, 2017. e-Pub 2017. PMID: 28117898.
- Short NJ, Kantarjian H, Jabbour E, Cortes JE, Thomas DA, Rytting ME, Daver N, Alvarado Y, Konopleva M, Kebriaei P, Wierda WG, DiNardo CD, Bivins C, McCue D, Richie MA, Ravandi F. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia. Br J Haematol. e-Pub 2017. PMID: 28616864.
- Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol 177(4):567-577, 2017. e-Pub 2017. PMID: 28295181.
- Gaballa S, Saliba R, Oran B, Brammer JE, Chen J, Rondon G, Alousi AM, Kebriaei P, Marin D, Popat UR, Andersson BS, Shpall EJ, Jabbour E, Daver N, Andreeff M, Ravandi F, Cortes J, Patel K, Champlin RE, Ciurea SO. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol 92(4):331-337, 2017. e-Pub 2017. PMID: 28052408.
- Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant 52(4):580-587, 2017. e-Pub 2017. PMID: 27991894.
- Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
- Brammer JE, Khouri I, Marin D, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Champlin RE, Hosing C, Kebriaei P. Stem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma 58(2):1-6, 2017. e-Pub 2017. PMID: 27348707.
- Issa GC, Kantarjian HM, Yin CC, Qiao W, Ravandi F, Thomas D, Short NJ, Sasaki K, Garcia-Manero G, Kadia TM, Cortes JE, Daver N, Borthakur G, Jain N, Konopleva M, Khouri I, Kebriaei P, Champlin RE, Pierce S, O'Brien SM, Jabbour E. Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease. Cancer 123(3):459-467, 2017. e-Pub 2017. PMID: 27696391.
- Srour SA, Milton DR, Bashey A, Karduss-Urueta A, Al Malki MM, Romee R, Solomon S, Nademanee A, Brown S, Slade M, Perez R, Rondon G, Forman SJ, Champlin RE, Kebriaei P, Ciurea SO. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant 23(2):318-324, 2017. e-Pub 2017. PMID: 27856368.
- Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123(2):294-302, 2017. e-Pub 2017. PMID: 27602508.
- Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, Maziarz RT, Champlin RE, Hosing C, Kebriaei P. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transplant 52(1):20-27, 2017. e-Pub 2017. PMID: 27618682.
- Oran B, Jorgensen JL, Marin D, Wang S, Ahmed S, Alousi AM, Andersson BS, Bashir Q, Bassett R, Lyons G, Chen J, Rezvani K, Popat U, Kebriaei P, Patel K, Rondon G, Shpall EJ, Champlin RE. Pretransplantion minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica 102(1):110-117, 2017. e-Pub 2017. PMID: 27540139.
- Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer 122(24):3831-3837, 2016. e-Pub 2016. PMID: 27680710.
- Short NJ, Kantarjian HM, Sasaki K, Cortes JE, Ravandi F, Thomas DA, Garcia-Manero G, Khouri I, Kebriaei P, Champlin RE, Pierce S, Issa GC, Konopleva M, Kadia TM, Bueso-Ramos C, Khoury JD, Jain N, O'Brien SM, Jabbour E. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Cancer 122(24):3812-3820, 2016. e-Pub 2016. PMID: 27508525.
- Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
- Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget MA, Datar V, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A 113(48):E7788-E7797, 2016. e-Pub 2016. PMID: 27849617.
- Alatrash G, Thall PF, Valdez BC, Fox PS, Ning J, Garber HR, Janbey S, Worth LL, Popat U, Hosing C, Alousi AM, Kebriaei P, Shpall EJ, Jones RB, de Lima M, Rondon G, Chen J, Champlin RE, Andersson BS. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 22(10):1792-800, 2016. e-Pub 2016. PMID: 27377901.
- Oliver N, Luong T, Tchakarov A, Abdelrahim M, Mulanovich VE, Kontoyiannis DP, Jones R, Kebriaei P, Samuels J, Glass W, Abudayyeh A. Disseminated cryptococcal infection in allogeneic stem cell transplant patients: a rare cause of acute kidney injury. Bone Marrow Transplant 51(10):1301-1304, 2016. e-Pub 2016. PMID: 27159179.
- Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-76, 2016. e-Pub 2016. PMID: 27482888.
- Gutierrez C, Kebriaei P, Turner KA, Yemelyanova A, Ariza-Heredia EJ, Foo WC. A unique presentation of acute liver failure from herpes simplex virus hepatitis. Transpl Infect Dis 18(4):592-4, 2016. e-Pub 2016. PMID: 27222930.
- Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant 51(7):999-1001, 2016. e-Pub 2016. PMID: 26950376.
- Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
- Thompson PA, Perera T, Marin D, Oran B, Popat U, Qazilbash M, Shah N, Parmar S, Rezvani K, Olson A, Kebriaei P, Anderlini P, Rondon G, Alousi A, Ciurea S, Champlin RE, Bajel A, Szer J, Shpall EJ, Ritchie D, Hosing CM. Double Umbilical Cord Blood Transplantation (dUCB) is effective therapy for relapsed or refractory Hodgkin Lymphoma. Leuk Lymphoma 57(7):1-23, 2016. e-Pub 2016. PMID: 26472485.
- Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant 22(5):961-5, 2016. e-Pub 2016. PMID: 26921820.
- Ravandi F, Jorgensen JL, O'Brien SM, Jabbour E, Thomas DA, Borthakur G, Garris R, Huang X, Garcia-Manero G, Burger JA, Ferrajoli A, Wierda W, Kadia T, Jain N, Wang SA, Konoplev S, Kebriaei P, Champlin RE, McCue D, Estrov Z, Cortes JE, Kantarjian HM. Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol 172(3):392-400, 2016. e-Pub 2016. PMID: 26492205.
- Milgrom SA, Nieto Y, Pinnix CC, Smith GL, Wogan CF, Rondon G, Medeiros LJ, Kebriaei P, Dabaja BS. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. J Med Case Rep 10:209, 2016. e-Pub 2016. PMID: 27465468.
- Ravandi F, O'Brien SM, Cortes JE, Thomas DM, Garris R, Faderl S, Burger JA, Rytting ME, Ferrajoli A, Wierda WG, Verstovsek S, Champlin R, Kebriaei P, McCue DA, Huang X, Jabbour E, Garcia-Manero G, Estrov Z, Kantarjian HM. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer 121(23):4158-64, 2015. e-Pub 2015. PMID: 26308885.
- Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk 15(11):687-93, 2015. e-Pub 2015. PMID: 26361647.
- Lee HC, Saliba RM, Rondon G, Chen J, Charafeddine Y, Medeiros LJ, Alatrash G, Andersson BS, Popat U, Kebriaei P, Ciurea S, Oran B, Shpall E, Champlin R. Mixed T-lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of AML/MDS. Biol Blood Marrow Transplant 21(11):1948-54, 2015. e-Pub 2015. PMID: 26183077.
- Kebriaei P. Allo-transplant for older patients with acute lymphoblastic leukemia: does it work?. Leuk Lymphoma 56(10):1-2, 2015. e-Pub 2015. PMID: 25721757.
- Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. BETTER ALLELE-LEVEL MATCHING IMPROVES TRANSPLANT RELATED MORTALITY AFTER DOUBLE CORD BLOOD TRANSPLANTATION. Haematologica 100(10):1361-70, 2015. e-Pub 2015. PMID: 26250579.
- Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia 29(9):1945-8, 2015. e-Pub 2015. PMID: 25721897.
- Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, Marin D, Shpall EJ, Champlin RE, Ciurea SO. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression Free Survival for Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. e-Pub 2015. PMID: 26343946.
- Oran B, Jimenez AM, De Lima M, Popat UR, Bassett R, Andersson BS, Borthakur G, Bashir Q, Chen J, Ciurea SO, Jabbour E, Cortes J, Kebriaei P, Khouri IF, Qazilbash MH, Ravandi F, Rondon G, Lu X, Shpall EJ, Champlin RE. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 21(8):1405-12, 2015. e-Pub 2015. PMID: 25840338.
- El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk 15(8):472-6, 2015. e-Pub 2015. PMID: 25963284.
- Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant 50(7):939-46, 2015. e-Pub 2015. PMID: 25867648.
- Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 50 Suppl 2:S55-62, 2015. e-Pub 2015. PMID: 26039209.
- Kebriaei P, Poon ML. Future of Therapy in Acute Lymphoblastic Leukemia (ALL)-Potential Role of Immune-Based Therapies. Curr Hematol Malig Rep 10(2):76-85, 2015. e-Pub 2015. PMID: 25899862.
- Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase Ii Trial Of Gvhd Prophylaxis with Post-Transplantation Cyclophosphamide Following Reduced-Intensity Busulfan/Fludarabine (Bu/Flu) Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
- Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
- Liadi I, Singh H, Romain G, Rey-Villamizar N, Merouane A, Adolacion JR, Kebriaei P, Huls H, Qiu P, Roysam B, Cooper LJ, Varadarajan N. Individual Motile CD4+ T Cells Can Participate in Efficient Multikilling through Conjugation to Multiple Tumor Cells. Cancer Immunol Res 3(5):473-82, 2015. e-Pub 2015. PMID: 25711538.
- Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SO. Can a Female Donor for a Male Recipient Decrease the Relapse Rate for Patients With Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation?. Biol Blood Marrow Transplant 21(4):713-9, 2015. e-Pub 2015. PMID: 25540936.
- Hobbs GS, Hamdi A, Hilden PD, Goldberg JD, Poon ML, Ledesma C, Devlin SM, Rondon G, Papadopoulos EB, Jakubowski AA, O'Reilly RJ, Champlin RE, Giralt S, Perales MA, Kebriaei P. Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts. Bone Marrow Transplant 50(4):493-8, 2015. e-Pub 2015. PMID: 25621808.
- Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. Short-term Cardiac Toxicity of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Leuk Lymphoma 56(2):1-8, 2015. e-Pub 2015. PMID: 24882259.
- Ariza-Heredia EJ, Gulbis AM, Stolar KR, Kebriaei P, Shah DP, McConn KK, Champlin RE, Chemaly RF. Vaccination guidelines after hematopoietic stem cell transplantation: practitioners' knowledge, attitudes, and gap between guidelines and clinical practice. Transpl Infect Dis 16(6):878-86, 2014. e-Pub 2014. PMID: 25405922.
- Di Stasi A, Milton DR, Poon LM, Hamdi A, Rondon G, Chen J, Pingali SR, Konopleva M, Kongtim P, Alousi A, Qazilbash MH, Ahmed S, Bashir Q, Al-atrash G, Oran B, Hosing CM, Kebriaei P, Popat U, Shpall EJ, Lee DA, de Lima M, Rezvani K, Khouri IF, Champlin RE, Ciurea SO. Similar Transplantation Outcomes for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with Haploidentical versus 10/10 Human Leukocyte Antigen-Matched Unrelated and Related Donors. Biol Blood Marrow Transplant 20(12):1975-81, 2014. e-Pub 2014. PMID: 25263628.
- Walker GV, Shihadeh F, Kantarjian H, Allen P, Rondon G, Kebriaei P, O'Brien S, Kedir A, Said M, Grant JD, Thomas DA, Gidley PW, Arzu I, Pinnix C, Reed V, Dabaja BS. Comprehensive craniospinal radiation for controlling central nervous system leukemia. Int J Radiat Oncol Biol Phys 90(5):1119-25, 2014. e-Pub 2014. PMID: 25539370.
- Hamdi A, Mawad R, Bassett R, di Stasi A, Ferro R, Afrough A, Ram R, Dabaja B, Rondon G, Champlin R, Sandmaier BM, Doney K, Bar M, Kebriaei P. Central Nervous System Relapse in Adults with Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(11):1767-71, 2014. e-Pub 2014. PMID: 25017763.
- Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Erkers T, Ho V, Kebriaei P, Keever-Taylor C, Kindwall-Keller T, Lazarus HM, Laughlin MJ, Lill M, O'Brien T, Perales MA, Rocha V, Savani BN, Szwajcer D, Valcarcel D, Eapen M. Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 20(9):1418-25, 2014. e-Pub 2014. PMID: 24892261.
- Bear AS, Hanley PJ, Bosque DM, Cruz CR, Kaur I, Liu H, Kebriaei P, Hosing C, Rezvani K, Oran B, De Lima MJ, Bollard CM, Shpall EJ. Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy 16(8):1153-7, 2014. e-Pub 2014. PMID: 24582458.
- Parmar S, de Lima M, Worth L, Petropoulos D, Lee D, Cooper L, Kongtim P, Alousi A, Hosing C, Popat U, Kebriaei P, McNiece I, Shpall E, Rondon G, Champlin R. Is there an expiration date for a cord blood unit in storage?. Bone Marrow Transplant 49(8):1109-12, 2014. e-Pub 2014. PMID: 24797184.
- Zhou Y, Slack R, Jorgensen JL, Wang SA, Rondon G, de Lima M, Shpall E, Popat U, Ciurea S, Alousi A, Qazilbash M, Hosing C, O'Brien S, Thomas D, Kantarjian H, Medeiros LJ, Champlin RE, Kebriaei P. The Effect of Peritransplant Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 14(4):319-26, 2014. e-Pub 2014. PMID: 24548609.
- Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE. Cytogenetics, Donor Type and use of Hypomethylating Agents in Myelodysplastic Syndrome with Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 2014. PMID: 24953017.
- Holmes HM, Des Bordes JK, Kebriaei P, Yennu S, Champlin RE, Giralt S, Mohile SG. Optimal screening for geriatric assessment in older allogeneic hematopoietic cell transplantation candidates. J Geriatr Oncol. e-Pub 2014. PMID: 24835889.
- Nadeem S, Hymes S, Kebriaei P, Abruzzo L, Curry JL, Duvic M. Alopecia areata after HLA-identical BMT from an affected, sibling donor. Bone Marrow Transplant 49(4):592-4, 2014. e-Pub 2014. PMID: 24442249.
- Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, Litzow MR, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: Impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia 28(3):658-65, 2014. e-Pub 2014. PMID: 23989431.
- Benjamini O, Dumlao TL, Kantarjian H, O'Brien S, Garcia-Manero G, Faderl S, Jorgensen J, Luthra R, Garris R, Thomas D, Kebriaei P, Champlin R, Jabbour E, Burger J, Cortes J, Ravandi F. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 89(3):282-7, 2014. e-Pub 2014. PMID: 24779033.
- Marks DI, Woo KA, Zhong X, Appelbaum FR, Bachanova V, Barker JN, Brunstein CG, Gibson J, Kebriaei P, Lazarus HM, Olsson R, Perales MA, Pidala J, Savani B, Rocha V, Eapen M. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors. Haematologica 99(2):322-8, 2014. e-Pub 2014. PMID: 24056817.
- Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ. The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2014. e-Pub 2014. PMID: 24169268.
- Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257(1):181-90, 2014. e-Pub 2014. PMID: 24329797.
- Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-8, 2013. e-Pub 2013. PMID: 23872222.
- Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 88(9):754-7, 2013. e-Pub 2013. PMID: 23749720.
- Wilhelm K, Chemaly R, Saliba R, Gulbis A, Saunders I, Cool R, Ferguson J, Westmoreland M, Rondon G, Kebriaei P. The impact of pre-transplant valganciclovir on early cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. J Oncol Pharm Pract. e-Pub 2013. PMID: 24022408.
- Kantarjian H, Thomas D, Jorgensen J, Kebriaei P, Jabbour E, Rytting M, York S, Ravandi F, Garris R, Kwari M, Faderl S, Cortes J, Champlin R, O'Brien S. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 119(15):2728-36, 2013. e-Pub 2013. PMID: 23633004.
- Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood 122(7):1214-21, 2013. e-Pub 2013. PMID: 23836561.
- Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z, Tykodi SS, Kebriaei P, Lee DA, Miller JC, Rebar EJ, Holmes MC, Jaenisch R, Champlin RE, Gregory PD, Cooper LJ. Towards eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 122(8):1341-9, 2013. e-Pub 2013. PMID: 23741009.
- Sasaki K, Lu G, Saliba RM, Bashir Q, Hosing C, Popat U, Shah N, Parmar S, Dinh Y, Ahmed S, Shpall EJ, Kebriaei P, Shah JJ, Orlowski RZ, Champlin R, Qazilbash MH. Impact of t(11;14)(q13;q32) on the Outcome of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Biol Blood Marrow Transplant 19(8):1227-32, 2013. e-Pub 2013. PMID: 23733001.
- Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) following relapse post allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant 19(7):1059-64, 2013. e-Pub 2013. PMID: 23644077.
- Kebriaei P, Wilhelm K, Ravandi F, Brandt M, de Lima M, Ciurea S, Worth L, O'Brien S, Thomas D, Champlin RE, Kantarjian H. Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin. Clin Lymphoma Myeloma Leuk 13(3):296-301, 2013. e-Pub 2013. PMID: 23313065.
- Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE. Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121(26):5113-23, 2013. e-Pub 2013. PMID: 23610374.
- Karuturi M, Hosing C, Fanale M, Medeiros LJ, Alousi AM, de Lima MJ, Qazilbash MH, Kebriaei P, Younes A, Khouri I, Andersson BS, Champlin R, Anderlini P, Popat U. High-dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Biol Blood Marrow Transplant 19(6):991-4, 2013. e-Pub 2013. PMID: 23507470.
- Poon LM, Bassett R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 48(5):666-70, 2013. e-Pub 2013. PMID: 23085830.
- Chen Y, Kantarjian H, Pierce S, Faderl S, O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, Daver N, Kadia T, Estrov Z, Garcia-Manero G, Cortes J, Ravandi F. Prognostic significance of 11q23 aberrations in adult acute myeloid leukemia and the role of allogeneic stem cell transplantation. Leukemia 27(4):836-42, 2013. e-Pub 2013. PMID: 23135353.
- Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 2013. e-Pub 2013. PMID: 23330820.
- Hosing C, Kebriaei P, Wierda W, Jena B, Cooper LJ, Shpall E. CARs in Chronic Lymphocytic Leukemia - Ready to Drive. Curr Hematol Malig Rep 8(1):60-70, 2013. e-Pub 2013. PMID: 23225251.
- Parmar S, Rondon G, de Lima M, Thall P, Bassett R, Anderlini P, Kebriaei P, Khouri I, Ganesan P, Champlin R, Giralt S. Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study. Biol Blood Marrow Transplant 19(3):474-80, 2013. e-Pub 2013. PMID: 23220013.
- Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-7, 2013. e-Pub 2013. PMID: 23128322.
- Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2013. e-Pub 2013. PMID: 22982533.
- Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJ. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother 36(2):112-23, 2013. e-Pub 2013. PMID: 23377665.
- Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant 48(1):26-31, 2013. e-Pub 2013. PMID: 22732703.
- Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, Champlin RE, Singh H, Cooper LJ. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp(72):e50070, 2013. e-Pub 2013. PMID: 23407473.
- Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ. Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells. PLoS One 8(5):e64138, 2013. e-Pub 2013. PMID: 23741305.
- Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1819-26, 2012. e-Pub 2012. PMID: 22750645.
- Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T Cell Replete Graft Compared with T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1835-44, 2012. e-Pub 2012. PMID: 22796535.
- de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. e-Pub 2012. PMID: 23234514.
- Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-86, 2012. e-Pub 2012. PMID: 22643322.
- Kebriaei P, Poon LM. The Role of Allogeneic Hematopoietic Stem Cell Transplantation in the Therapy of Patients with Acute Lymphoblastic Leukemia. Curr Hematol Malig Rep 7(2):144-52, 2012. e-Pub 2012. PMID: 22410763.
- Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, Huls H, Miller JC, Kebriaei P, Rabinovitch B, Lee DA, Champlin RE, Bonini C, Naldini L, Rebar EJ, Gregory PD, Holmes MC, Cooper LJ. A foundation for "universal" T-cell based immunotherapy: T-cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119(24):5697-705, 2012. e-Pub 2012. PMID: 22535661.
- Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood 119(26):6373-8, 2012. e-Pub 2012. PMID: 22586182.
- Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJ. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 23(5):444-50, 2012. e-Pub 2012. PMID: 22107246.
- Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, Melphalan, Thiotepa and ATG Conditioning for Unrelated Cord Blood Transplantation. Leuk Lymphoma 53(5):901-6, 2012. e-Pub 2012. PMID: 21988645.
- Kantarjian H, Thomas D, Jorgensen J, Jabbour E, Kebriaei P, Rytting M, York S, Ravandi F, Kwari M, Faderl S, Rios MB, Cortes J, Fayad L, Tarnai R, Wang SA, Champlin R, Advani A, O'Brien S. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13(4):403-11, 2012. e-Pub 2012. PMID: 22357140.
- Kebriaei P, Saliba R, Rondon G, Chiattone A, Luthra R, Anderlini P, Andersson B, Shpall E, Popat U, Jones R, Worth L, Ravandi F, Thomas D, O'Brien S, Kantarjian H, de Lima M, Giralt S, Champlin R. Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes. Biol Blood Marrow Transplant 18(4):584-92, 2012. e-Pub 2012. PMID: 21867666.
- Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 47(2):212-6, 2012. e-Pub 2012. PMID: 21423123.
- Ji Y, Feng L, Liu P, Shpall EJ, Kebriaei P, Champlin R, Berry D, Cooper LJ. Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size. J Biopharm Stat 22(6):1206-19, 2012. e-Pub 2012. PMID: 23075018.
- Alatrash G, Pelosini M, Saliba RM, Koca E, Rondon G, Andersson BS, Chiattone A, Zhang W, Giralt SA, Cernosek AM, Kebriaei P, Alousi AM, Popat UR, Hosing C, Khouri IF, Champlin RE, de Lima MJ. Platelet Recovery Prior to Allogeneic Stem Cell Transplant Predicts Posttransplant Outcomes in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant 17(12):1841-5, 2011. e-Pub 2011. PMID: 21684343.
- Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S, Chen J, Qazilbash M, Kebriaei P, Konopleva M, Andreeff M, Cortes J, McCue D, Kantarjian H, Champlin RE, de Lima M. Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation with Sorafenib. Biol Blood Marrow Transplant 17(12):1874-7, 2011. e-Pub 2011. PMID: 21767516.
- Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86(11):954-6, 2011. e-Pub 2011. PMID: 21948087.
- Raval M, Gulbis A, Bollard C, Leen A, Chemaly R, Shpall E, Lahoti A, Kebriaei P. Evaluation and Management of BK Virus-Associated Nephropathy following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 17(11):1589-93, 2011. e-Pub 2011. PMID: 21767514.
- Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life. Biol Blood Marrow Transplant 17(10):1490-6, 2011. e-Pub 2011. PMID: 21338705.
- Andersson BS, Valdez BC, de Lima M, Wang X, Thall PF, Worth LL, Popat U, Madden T, Hosing C, Alousi A, Rondon G, Kebriaei P, Shpall EJ, Jones RB, Champlin RE. Clofarabine±Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS. Biol Blood Marrow Transplant 17(6):893-900, 2011. e-Pub 2011. PMID: 20946966.
- Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, Lima MD, Kantarjian H, Ravandi F. Persistence of Cytogenetic Abnormalities at Complete Remission After Induction in Patients With Acute Myeloid Leukemia: Prognostic Significance and the Potential Role of Allogeneic Stem-Cell Transplantation. American Society of Clinical Oncology (ASCO) 29(18):2507-2513, 2011. e-Pub 2011.
- Ciurea SO, Saliba RM, Rondon G, Patah PA, Aung F, Cano P, Andersson BS, Kebriaei P, Popat U, Fernandez-Vina M, Champlin RE, de Lima M. Outcomes of patients with myeloid malignancies treated with allogeneic hematopoietic stem cell transplantation from matched unrelated donors compared with one-human leukocyte antigen mismatched related donors using HLA typing at 10 loci,. Biol Blood Marrow Transplant 17(6):923-9, 2011. e-Pub 2011. PMID: 20969970.
- Champlin R, Jabbour E, Kebriaei P, Anderlini P, Andersson B, de Lima M. Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S96-100, 2011. e-Pub 2011. PMID: 22035758.
- Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol 29(18):2507-13, 2011. e-Pub 2011. PMID: 21555694.
- Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 71(10):3516-27, 2011. e-Pub 2011. PMID: 21558388.
- Kebriaei P, Simon R. Mesenchymal Stem Cell Therapy in the Treatment of Acute and Chronic Graft versus Host Disease. Frontiers in Hematology Oncology 1:1-8, 2011. e-Pub 2011.
- Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biol Blood Marrow Transplant 17(3):412-20, 2011. e-Pub 2011. PMID: 20674757.
- Jabbour E, Cortes J, Santos FP, Jones D, O'Brien S, Rondon G, Popat U, Giralt S, Kebriaei P, Jones RB, Kantarjian H, Champlin R, de Lima M. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 117(13):3641-7, 2011. e-Pub 2011. PMID: 21156844.
- Choi Y, Yuen C, Maiti SN, Olivares S, Gibbons H, Huls H, Raphael R, Killian TC, Stark DJ, Lee DA, Torikai H, Monticello D, Kelly SS, Kebriaei P, Champlin RE, Biswal SL, Cooper LJ. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices 12(5):855-63, 2010. e-Pub 2010. PMID: 20574820.
- Ravandi F, O'Brien S, Thomas D, Faderl S, Jones D, Garris R, Dara S, Jorgensen J, Kebriaei P, Champlin R, Borthakur G, Burger J, Ferrajoli A, Garcia-Manero G, Wierda W, Cortes J, Kantarjian H. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood 116(12):2070-7, 2010. e-Pub 2010. PMID: 20466853.
- Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH. Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma. Biol Blood Marrow Transplant 16(8):1122-9, 2010. e-Pub 2010. PMID: 20178853.
- Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 70(10):3915-24, 2010. e-Pub 2010. PMID: 20424114.
- Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ. piggyBac transposon/transposase system to generate CD19-specific T cells for treatment of B-lineage malignancies. Hum Gene Ther. e-Pub 2010. PMID: 19905893.
- Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-36, 2010. e-Pub 2010. PMID: 19668237.
- Hosing C, Munsell MF, Reuben JM, Popat U, Lee BN, Gao H, Körbling M, Shpall EJ, Kebriaei P, Alousi A, De Lima M, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas. J Blood Med 1:49-55, 2010. e-Pub 2010. PMID: 22282683.
- Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 2009. e-Pub 2009. PMID: 19654407.
- Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J. Adult Human Mesenchymal Stem Cells Added to Corticosteroid Therapy for the Treatment of Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant 15(7):804-11, 2009. e-Pub 2009. PMID: 19539211.
- Martin PJ, Bachier CR, Klingemann HG, McCarthy PL, Szabolcs P, Uberti JP, Schuster MW, Weisdorf D, Chao NJ, Kebriaei P, Shpall EJ, Macmillan ML, Soiffer RJ. Endpoints for Clinical Trials Testing Treatment of Acute Graft-versus-Host Disease: A Joint Statement. Biol Blood Marrow Transplant 15(7):777-84, 2009. e-Pub 2009. PMID: 19539208.
- Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 2009. e-Pub 2009. PMID: 19384931.
- Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718-23, 2009. e-Pub 2009. PMID: 19450756.
- De Padua Silva L, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia-Manero G, Champlin R, Issa JP, Ravandi F. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43(11):839-43, 2009. e-Pub 2009. PMID: 19151791.
- Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer 115(9):1899-905, 2009. e-Pub 2009. PMID: 19235255.
- Verma D, O'Brien S, Thomas D, Faderl S, Koller C, Pierce S, Kebriaei P, Garcia-Manero G, Cortes J, Kantarjian H, Ravandi F. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens. Cancer 115(1):101-6, 2009. e-Pub 2009. PMID: 19090005.
- Vega-Ruiz A, O'Brien S, Cortes J, Kebriaei P, Thomas D, Kantarjian H, Ravandi F. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate. Leuk Res 32(9):1468-71, 2008. e-Pub 2008. PMID: 18355919.
- Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5):786-92, 2008. e-Pub 2008. PMID: 18564354.
- Hosing C, Saliba RM, Okoroji GJ, Popat U, Couriel D, Ali T, De Padua Silva L, Kebriaei P, Alousi A, De Lima M, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients >65 years of age. Ann Oncol 19(6):1166-71, 2008. e-Pub 2008. PMID: 18272911.
- Gordon MK, Sher D, Karrison T, Kebriaei P, Chuang K, Zhang Y, McDonnell D, Artz A, Godley L, Odenike O, Rich E, Michaelis L, Thirman MJ, Wickrema A, van Besien K, Larson RA, Stock W. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma 49(3):531-7, 2008. e-Pub 2008. PMID: 18297531.
- de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. Leukemia 22(2):258-64, 2008. e-Pub 2008. PMID: 17989720.
- Oran B, Giralt S, Couriel D, Hosing C, Shpall EJ, de Meis E, Khouri IF, Qazilbash M, Anderlini P, Kebriaei P, Popat U, Carrasco-Yalan A, Champlin RE, de Lima M. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 21(12):2540-4, 2007. e-Pub 2007. PMID: 17611563.
- Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D, Khouri IF, Anderlini P, Hosing C, Alousi A, Champlin RE, de Lima M. Long-term follow-up of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning for patients with chronic myeloid leukemia. Blood 110(9):3456-62, 2007. e-Pub 2007. PMID: 17652620.
- Qazilbash MH, Saliba RM, Ahmed B, Parikh G, Mendoza F, Ashraf N, Hosing C, Flosser T, Weber DM, Wang M, Couriel DR, Popat U, Kebriaei P, Alousi AM, Anderlini P, Naeem RC, Champlin RE, Giralt SA. Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 13(9):1066-72, 2007. e-Pub 2007. PMID: 17697969.
- Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F, Shpall E, Kebriaei P, Champlin R, de Lima M. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 110(2):340-344, 2007. e-Pub 2007. PMID: 17559140.
- Aribi A, Bueso-Ramos C, Estey E, Estrov Z, O'Brien S, Giles F, Faderl S, Thomas D, Kebriaei P, Garcia-Manero G, Pierce S, Cortes J, Kantarjian H, Ravandi F. Biphenotypic acute leukaemia: a case series. Br J Haematol 138(2):213-216, 2007. e-Pub 2007. PMID: 17593028.
- Oran B, Giralt S, Saliba R, Hosing C, Popat U, Khouri I, Couriel D, Qazilbash M, Anderlini P, Kebriaei P, Ghosh S, Carrasco-Yalan A, de Meis E, Anagnostopoulos A, Donato M, Champlin RE, de Lima M. Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biol Blood Marrow Transplant 13(4):454-462, 2007. e-Pub 2007. PMID: 17382251.
- Qazilbash MH, Saliba RM, Hosing C, Mendoza F, Qureshi SR, Weber DM, Wang M, Flosser T, Couriel DR, De Lima M, Kebriaei P, Popat U, Alousi AM, Champlin RE, Giralt SA. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 39(5):279-83, 2007. e-Pub 2007. PMID: 17262062.
- Kebriaei P, Saliba RM, Ma C, Ippoliti C, Couriel DR, de Lima M, Giralt S, Qazilbash MH, Gajewski JL, Ha CS, Champlin RE, Khouri IF. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia. Bone Marrow Transplant 38(3):203-9, 2006. e-Pub 2006. PMID: 16799614.
- Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Körbling M, Champlin RE. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133(5):533-7, 2006. e-Pub 2006. PMID: 16681642.
- Kebriaei P, Kline J, Stock W, Kasza K, Le Beau MM, Larson RA, van Besien K. Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplant 35(10):965-70, 2005. e-Pub 2005. PMID: 15806131.
- Kebriaei P, Winter JN, Laport GG, Le Beau MM, Dewald G, Larson RA. Multiple unrelated clonal abnormalities in host bone marrow cells after allogeneic stem cell transplantation. Leuk Res 28(5):537-40, 2004. e-Pub 2004. PMID: 15068908.
- Rimm DL, Koslov ER, Kebriaei P, Cianci CD, Morrow JS. Alpha 1(E)-catenin is an actin-binding and -bundling protein mediating the attachment of F-actin to the membrane adhesion complex. Proc Natl Acad Sci U S A 92(19):8813-7, 1995. e-Pub 1995. PMID: 7568023.
- Rimm DL, Kebriaei P, Morrow JS. Molecular cloning reveals alternative splice forms of human alpha(E)-catenin. Biochem Biophys Res Commun 203(3):1691-9, 1994. e-Pub 1994. PMID: 7945318.
Invited Articles
- Tewari P, Kebriaei P. Hematopoetic Stem Cell Transplantation in Adolescents and Young Adults. Acta Haematologica 132(3-4):313-325, 2014. e-Pub 2014.
- Kebriaei P, Kelly SS, Manuri P, Jena B, Jackson R, Shpall E, Champlin R, Cooper LJ. Chimeric antibody receptors (CARs): Driving T-cell specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed) 4:520-31, 2012. e-Pub 2012. PMID: 22202074.
- Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am 23(5):1043-63, vi, 2009. e-Pub 2009. PMID: 19825452.
- Ravandi F, Kebriaei P. Cytokines in the treatment of acute leukemias. Cancer Treat Res 126:313-31, 2005. e-Pub 2005. PMID: 16209072.
- Kebriaei P, Larson RA. Progress and challenges in the therapy of adult acute lymphoblastic leukemia. Curr Opin Hematol 10(4):284-9, 2003. e-Pub 2003. PMID: 12799534.
- Kebriaei P, Anastasi J, Larson RA. Acute lymphoblastic leukaemia: diagnosis and classification. Best Pract Res Clin Haematol 15(4):597-621, 2002. e-Pub 2002. PMID: 12617866.
- Kebriaei P, Robinson S. Experience with mesenchymal stromal cells in the treatment of acute and chronic graft versus host disease. Cytotherapy.
Review Articles
- Marcoux, C, Kebriaei, P. SOHO State of the Art Updates and Next Questions | Transplant in Adult Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 25(10):689-697, 2025. e-Pub 2025. PMID: 40383653.
- Locke, FL, Mahmoudjafari, Z, Kebriaei, P, Gardner, RA, Frigault, M, Frey, NV, Komanduri, KV, Perales, MA, Nikiforow, S. Awakening from REMS. Transplantation and Cellular Therapy 31(6):349.e1-349.e12, 2025. e-Pub 2025. PMID: 39954962.
- Smallbone, PI, Kebriaei, P, Mendt Vilchez, MC, Shpall, E, Olson, AL, Fingrut, WB. Mesenchymal stem cells in hematology. Best Practice and Research: Clinical Haematology 38(1), 2025. e-Pub 2025. PMID: 40274341.
- Marcoux C, Kebriaei P. Transplant in ALL: who, when, and how?. Hematology Am Soc Hematol Educ Program 2024(1):93-101, 2024. e-Pub 2024. PMID: 39644076.
- Shaffer BC, Kebriaei P, de Lima M, Jimenez Jimenez AM. Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice. Bone Marrow Transplant 60(2):128-134, 2024. e-Pub 2024. PMID: 39562717.
- Rahman ZA, Kebriaei P. SOHO State of the Art Updates and Next Questions | Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia in Adults. Clin Lymphoma Myeloma Leuk 23(11):779-785, 2023. e-Pub 2023. PMID: 37438208.
- Pasvolsky O, Kebriaei P, Shah BD, Jabbour E, Jain N. Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia. Blood Adv 7(14):3350-3360, 2023. e-Pub 2023. PMID: 36912764.
- Sanchez-Petitto G, Rezvani K, Daher M, Rafei H, Kebriaei P, Shpall EJ, Olson A. Umbilical Cord Blood Transplantation. Stem Cells Transl Med 12(2):55-71, 2023. e-Pub 2023. PMID: 36779789.
- Pasvolsky O, Daher M, Alatrash G, Marin D, Daver N, Ravandi F, Rezvani K, Shpall E, Kebriaei P. CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. Front Oncol 11, 2022. e-Pub 2022. PMID: 35083154.
- Kim K, Jabbour E, Short NJ, Kebriaei P, Kantarjian H, Ravandi F. Current Approaches to Philadelphia Chromosome–Positive B-Cell Lineage Acute Lymphoblastic Leukemia. Curr Oncol Rep 23(8), 2021. e-Pub 2021. PMID: 34125415.
- Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Hernandez Tejada FN, Martin PL, Auletta J, Choi SW, Bajwa R, Dailey Garnes N, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol 18(7):435-453, 2021. e-Pub 2021. PMID: 33608690.
- Greenbaum U, Kebriaei P, Srour SA, Olson A, Bashir Q, Neelapu SS, Rezvani K, Shpall EJ. Chimeric antigen receptor T-cell therapy toxicities. Br J Clin Pharmacol 87(6):2414-2424, 2021. e-Pub 2021. PMID: 32463929.
- Kamal M, Joseph J, Greenbaum U, Hicklen R, Kebriaei P, Srour SA, Wang XS. Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther 27(5):390.e1-390.e7, 2021. e-Pub 2021. PMID: 33965176.
- Ragoonanan D, Khazal SJ, Mejia R, Ewing L, Durand JB, Bashoura L, Tayar J, Dailey Garnes N, Petropoulos D, Tewari P, Bhatti M, Ahmad AH, Cortes J, Razvi S, McBeth K, Swinford R, Shoberu B, Waseemuddin W, Chi L, Gill JB, Zaky W, Daw N, Gutierrez C, Tereffe W, Kebriaei P, Rezvani K, Shpall EJ, Champlin RE, Mahadeo KM. Case Discussion and Literature Review. Front Oncol 11, 2021. e-Pub 2021. PMID: 33614514.
- Khazal S, Kebriaei P. Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20(11):713-719, 2020. e-Pub 2020. PMID: 32694050.
- Greenbaum U, Yalniz FF, Srour SA, Rezvani K, Singh H, Olson A, Blumenschein G, Hong DS, Shpall EJ, Kebriaei P. Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. Biol Blood Marrow Transplant 26(10):1759-1769, 2020. e-Pub 2020. PMID: 32623078.
- Muffly L, Kebriaei P. Philadelphia chromosome positive acute lymphoblastic leukemia in adults: Therapeutic options and dilemmas in 2020. Semin Hematol 57(3):137-141, 2020. e-Pub 2020. PMID: 33256903.
- Mahadeo KM, Bajwa R, Abdel-Azim H, Lehmann LE, Duncan C, Zantek N, Vittorio J, Angelo J, McArthur J, Schadler K, Chan S, Tewari P, Khazal S, Auletta JJ, Choi SW, Shoberu B, Kalwak K, Harden A, Kebriaei P, Abe JI, Li S, Moffet JR, Abraham S, Tambaro FP, Kleinschmidt K, Richardson PG, Corbacioglu S, Lung Injury PA, Network SI, for Blood TPDWPOTES, Transplantation M. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol 7(1):e61-e72, 2020. e-Pub 2020. PMID: 31818728.
- Greenbaum U, Mahadeo KM, Kebriaei P, Shpall EJ, Saini NY. Chimeric Antigen Receptor T-Cells in B-Acute Lymphoblastic Leukemia: State of the Art and Future Directions. Front Oncol 10:1594, 2020. e-Pub 2020. PMID: 32984022.
- DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, Fanning S, Inamoto Y, Kansagra A, Johnston L, Nagler A, Sauter CS, Savani BN, Perales MA, Carpenter PA, Larson RA, Weisdorf D. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25(11):2113-2123, 2019. e-Pub 2019. PMID: 31446198.
- Mahadeo KM, Khazal SJ, Abdel-Azim H, Fitzgerald JC, Taraseviciute A, Bollard CM, Tewari P, Duncan C, Traube C, McCall D, Steiner ME, Cheifetz IM, Lehmann LE, Mejia R, Slopis JM, Bajwa R, Kebriaei P, Martin PL, Moffet J, McArthur J, Petropoulos D, O'Hanlon Curry J, Featherston S, Foglesong J, Shoberu B, Gulbis A, Mireles ME, Hafemeister L, Nguyen C, Kapoor N, Rezvani K, Neelapu SS, Shpall EJ, Lung Injury PA, Network SI. Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol 16(1):45-63, 2019. e-Pub 2019. PMID: 30082906.
- Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47-62, 2018. e-Pub 2018. PMID: 28925994.
- Hill L, Alousi A, Kebriaei P, Mehta R, Rezvani K, Shpall E. New and emerging therapies for acute and chronic graft versus host disease. Ther Adv Hematol 9(1):21-46, 2018. e-Pub 2018. PMID: 29317998.
- Kebriaei P, Izsvák Z, Narayanavari SA, Singh H, Ivics Z. Gene Therapy with the Sleeping Beauty Transposon System. Trends Genet 33(11):852-870, 2017. e-Pub 2017. PMID: 28964527.
- Perales MA, Kebriaei P, Kean LS, Sadelain M. Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. Biol Blood Marrow Transplant. e-Pub 2017. PMID: 29032264.
- Kongtim P, Lee DA, Cooper LJ, Kebriaei P, Champlin RE, Ciurea SO. Haploidentical Hematopoietic Stem Cell Transplantation as Platform for Post-transplant Cellular Therapy. Biol Blood Marrow Transplant 21(10):1714-20, 2015. e-Pub 2015. PMID: 26172479.
- Shah N, Rezvani K, Hosing C, Kebriaei P, Wierda W, Cooper L, Shpall E. Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective. Clin Lymphoma Myeloma Leuk 14 Suppl:S18-22, 2014. e-Pub 2014. PMID: 25486950.
- Tewari P, Franklin AR, Tarek N, Askins MA, Mofield S, Kebriaei P. Hematopoietic stem cell transplantation in adolescents and young adults. Acta Haematol 132(3-4):313-25, 2014. e-Pub 2014. PMID: 25228557.
- Kebriaei P, Robinson S. Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy 13(3):262-8, 2011. e-Pub 2011. PMID: 21231805.
- Horwitz EM, Maziarz RT, Kebriaei P. MSCs in hematopoietic cell transplantation. Biol Blood Marrow Transplant 17(1 Suppl):S21-9, 2011. e-Pub 2011. PMID: 21195306.
- Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9 Suppl 3:S261-5, 2009. e-Pub 2009. PMID: 19778850.
- Ravandi F, Faderl S, Kebriaei P, Kantarjian H. Modern treatment programs for adults with acute lymphoblastic leukemia. Curr Hematol Malig Rep 2(3):169-75, 2007. e-Pub 2007. PMID: 20425366.
Other Articles
- Boyiadzis M, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Bacher U, Badar T, Badawy SM, Battiwalla M, Bejanyan N, Bhatt VR, Brown VI, Castillo P, Cerny J, Copelan EA, Craddock C, Dholaria B, Perez MAD, Ebens CL, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Iqbal M, Jamy O, Kharfan-Dabaja MA, Khera N, Lazarus HM, Lin R, Modi D, Nathan S, Nishihori T, Patel SS, Pawarode A, Saber W, Sharma A, Solh M, Wagner JL, Wang T, Williams KM, Winestone LE, Wirk B, Zeidan A, Hourigan CS, Litzow M, Kebriaei P, de Lima M, Page K, Weisdorf DJ Correction to. Leukemia 37(5):1173, 2023. PMID: 36949156.
- Jimenez Jimenez AM, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen K, Abdel-Azim H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez MAD, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Khera N, Krem MM, Lazaryan A, Maakaron J, Martino R, McGuirk J, Michelis FV, Milone G, Mishra A, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Patel S, Saad A, Seo S, Sharma A, Solh M, Verdonck LF, Wirk B, Yared JA, Litzow M, Kebriaei P, Hourigan CS, Saber W, Weisdorf D Correction to. Bone Marrow Transplant 57(5):852, 2022. PMID: 35297406.
- Percival ME, Wang HL, Zhang MJ, Saber W, de Lima M, Litzow M, Kebriaei P, Abdel-Azim H, Adekola K, Aljurf M, Bacher U, Badawy SM, Beitinjaneh A, Bejanyan N, Bhatt V, Byrne M, Cahn JY, Castillo P, Chao N, Chhabra S, Copelan E, Cutler C, DeFilipp Z, Dias A, Diaz MA, Estey E, Farhadfar N, Frangoul HA, Freytes CO, Gale RP, Ganguly S, Gowda L, Grunwald M, Hossain N, Kamble RT, Kanakry CG, Kansagra A, Kharfan-Dabaja MA, Krem M, Lazarus HM, Lee JW, Liesveld JL, Lin R, Liu H, McGuirk J, Munker R, Murthy HS, Nathan S, Nishihori T, Olsson RF, Palmisiano N, Passweg JR, Prestidge T, Ringdén O, Rizzieri DA, Rybka WB, Savoie ML, Schultz KR, Seo S, Sharma A, Solh M, Strair R, van der Poel M, Verdonck LF, Yared JA, Weisdorf D, Sandmaier BM Correction to. Bone Marrow Transplant 56(9):2319, 2021. PMID: 34017072.
- Lazaryan A, Dolan M, Zhang MJ, Wang HL, Kharfan-Dabaja MA, Marks DI, Bejanyan N, Copelan E, Majhail NS, Waller EK, Chao N, Prestidge T, Nishihori T, Kebriaei P, Inamoto Y, Hamilton B, Hashmi SK, Kamble RT, Bacher U, Hildebrandt GC, Stiff PJ, McGuirk J, Aldoss I, Beitinjaneh AM, Muffly L, Vij R, Olsson RF, Byrne M, Schultz KR, Aljurf M, Seftel M, Savoie ML, Savani BN, Verdonck LF, Cairo MS, Hossain N, Bhatt VR, Frangoul HA, Abdel-Azim H, Al Malki M, Munker R, Rizzieri D, Khera N, Nakamura R, Ringdén O, Van der Poel M, Murthy HS, Liu H, Mori S, De Oliveira S, Bolaños-Meade J, Elsawy M, Barba P, Nathan S, George B, Pawarode A, Grunwald M, Agrawal V, Wang Y, Assal A, Caro PC, Kuwatsuka Y, Seo S, Ustun C, Politikos I, Lazarus HM, Saber W, Sandmaier BM, De Lima M, Litzow M, Bachanova V, Weisdorf D Erratum. Haematologica 106(8):2295-2296, 2021. PMID: 34333962.
- Wieduwilt MJ, Stock W, Advani A, Luger S, Larson RA, Tallman M, Appelbaum F, Zhang MJ, Bo-Subait K, Wang HL, Bhatt VR, Dholaria B, Eapen M, Hamadani M, Jamy O, Prestidge T, Pulsipher M, Ritchie D, Rizzieri D, Sharma A, Barba P, Sandmaier BM, de Lima M, Kebriaei P, Litzow M, Saber W, Weisdorf D Correction. Leukemia 35(7):2140, 2021. PMID: 34088982.
- Ragoonanan D, Khazal SJ, Abdel-Azim H, McCall D, Cuglievan B, Tambaro FP, Ahmad AH, Rowan CM, Gutierrez C, Schadler K, Li S, Di Nardo M, Chi L, Gulbis AM, Shoberu B, Mireles ME, McArthur J, Kapoor N, Miller J, Fitzgerald JC, Tewari P, Petropoulos D, Gill JB, Duncan CN, Lehmann LE, Hingorani S, Angelo JR, Swinford RD, Steiner ME, Tejada FNH, Martin PL, Auletta J, Choi SW, Bajwa R, Garnes ND, Kebriaei P, Rezvani K, Wierda WG, Neelapu SS, Shpall EJ, Corbacioglu S, Mahadeo KM Author Correction. Nat Rev Clin Oncol 18(7):468, 2021. PMID: 33731864.
Editorials
- Kebriaei P. Mesenchymal Stromal Cells The magic Band-Aid. Acta Haematol 133(1):70-71, 2015. PMID: 25139435.
- Ravandi F, Kebriaei P. Treatment for Adult ALL. International Journal of Hematology and Oncology 2(1):5-8, 2013.
Book Chapters
- Afrough, A, Im, JS, Jain, N, Kebriaei, P. Chimeric Antigen Receptor T-Cell Therapy in Acute Lymphoblastic Leukemia, 233-245, 2023.
- Greenbaum, U, Ramdial, JL, Afrough, A, Alsfeld, LC, Ghanem, S, Daher, M, Olson, AL, Kebriaei, P, Strati, P, Steiner, RE, Ahmed, S, Tanner, MR, Neelapu, SS, Rezvani, K, Shpall, E. Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy, 509-524, 2023.
- Khazal, SJ, Kebriaei, P. Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia, 217-232, 2023.
- Gutierrez, C, Pasvolsky, O, Kebriaei, P. CAR T-Cell Therapy and Critical Care Considerations, 427-435, 2023.
- Kebriaei P, Ravandi F, De Lima M, Champlin R. Management of Acute Leukemias in Cancer. In: Principles and Practice of Oncology. 12th. De Vita, Hellman, Rosenberg, 2023.
- Poon, ML, Kebriaei, P. Hematopoietic Cell Transplantation (HCT) for Acute Lymphoblastic Leukemia (ALL), 193-204, 2021.
- Poon M, Champlin R, Kebriaei P. Principles of Hematopoietic. In: Principles and Practice of Transplant Infectious Diseases. Springer Publications, 153-163, 2019.
- Di Stasi A, Kebriaei P. Allogeneic stem cell transplantation in MDS. In: Expert Clinical Perspective: Controversies and Uncertainties in Diagnosis & Management of Cancer. Wiley-Blackwell Health Sciences, 2013.
- Poon Limei M, Kebriaei P. Hematopoietic Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia (Excluding Ph+ ALL). In: Current Concepts and Controversies in Hematopoietic Cell Transplantation. Cambridge University, 144-152, 2012.
- Kebriaei P. The Role of Hematopoietic Stem Cell Transplantation in the Therapy of Adult Acute Lymphoblastic Leukemia. In: Leukemia Principles and Practice of Therapy. Blackwell Publishing, 250-258, 2011.
- Champlin R, Estey E, Kebriaei P, and de Lima M. Management of Acute Leukemias in Cancer. In: Principles and Practice of Oncology. 8th, 9th, 10th and 11th, 2008.
- Kebriaei P, Giralt S. The role of autologous stem cell transplantation in the management of acute lymphoblastic leukemia in adults. In: Springer. Springer Publications, 2007.
- Kebriaei P, Champlin R. The role of allogeneic stem cell transplantation in the therapy of adult acute lymphoblastic leukemia (ALL). in press. In: Springer. Springer Publications, 2007.
- Kebriaei P, Ravandi F. Cytokines in the treatment of acute leukemias. in press. . In: Cytokines and Cancer. Kluwer Academic Publishers, 2005.
- Kebriaei P, Stock W. Allogeneic stem cell transplantation for adult acute lymphoblastic leukemia. In: Allogeneic Stem Cell Transplantation: Clinical Research and Practice. Humana Press, 2002.
Letters to the Editor
- Mehta, RS, Aljawai, YM, Fingrut, WB, Smallbone, PI, Rondon, G, Olson, AL, Oran, B, Kebriaei, P, Champlin, RE, Shpall, E. Uncoupling toxicity from efficacy in donor selection for allogeneic hematopoietic cell transplantation. Journal of Hematology and Oncology 19, 2026.
- Subramanian, NG, Guffey, D, Avery, J, Garcia, D, Basom, R, Lee, SJ, Klein, K, Kebriaei, P, Rondon, G, Shpall, E, Jin, S, Young, E, Rojas Hernandez, CM, Li, A. Clinical Factors Associated With Catheter-Related VTE in Patients Undergoing Hematopoietic Cell Transplantation. American journal of hematology 100: 1463-1466, 2025.
- Rafaeli, N, Costa, DM, Ledesma, C, Jain, N, Tewari, P, Khouri, IF, Al-Atrash, G, Short, NJ, Jabbour, EJ, Rezvani, K, Alousi, AM, Popat, UR, Champlin, RE, Shpall, E, Kebriaei, P. Allogeneic Hematopoietic Stem Cell Transplantation Following CAR T Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia 25: e374-e377, 2025.
- De Lima, M, Kebriaei, P, Lanza, F, Cho, C, Popradi, G, Kaur, M, Zhang, MJ, Zhang, F, Shah, R, Vandendries, E, Asomaning, K, Dorman, S, Stelljes, M, Marks, DI, Saber, W. Five-Year Real-World Safety of Inotuzumab Ozogamicin Before Hematopoietic Stem Cell Transplantation in B-Cell Precursor Acute Lymphoblastic Leukemia. American journal of hematology 100: 909-912, 2025.
- Ravandi, F, Senapati, J, Jain, N, Short, NJ, Kadia, TM, Borthakur, G, Konopleva, M, Wierda, WG, Huang, X, Maiti, A, Issa, GC, Balkin, H, Garris, R, Ferrajoli, A, Garcia-Manero, G, Alvarado, Y, Kebriaei, P, Jabbour, EJ, Kantarjian, HM. Longitudinal follow up of a phase 2 trial of venetoclax added to hyper-CVAD, nelarabine and pegylated asparaginase in patients with T-cell acute lymphoblastic leukemia and lymphoma. Leukemia 38: 2717-2721, 2024.
- Marcoux C, Pasyar S, Milton DR, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Neupane N, Lee HC, Patel KK, Tang G, Aljawai Y, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH, Pasvolsky O. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. Br J Haematol 206: 763-765, 2024.
- Hegde PS, Andrew G, Gui G, Ravindra N, Mukherjee D, Wong ZC, Auletta JJ, El Chaer F, Corner A, Devine SM, Jimenez Jimenez AM, De Lima MJG, Litzow MR, Kebriaei P, Saber W, Spellman SR, Zeger SL, Page KM, Dillon LW, Hourigan CS. Measurable residual FLT3 tyrosine kinase domain mutations before allogeneic transplant for acute myeloid leukemia. Bone Marrow Transplant 60: 175-177, 2024.
- Malek AE, Al-Juhaishi T, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Faisal MS, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich VE, Ahmed S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant 59: 699-704, 2024.
- Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 204: e11-e16, 2024.
- Desikan, SP, Senapati, J, Jabbour, EJ, Abuasab, T, Short, NJ, Tang, G, Wang, S, Kebriaei, P, Kadia, TM, Borthakur, G, Ravandi-Kashani, F, Roberts, KG, Mullighan, CG, Konopleva, M, Kantarjian, HM, Jain, N. Outcomes of adult patients with relapsed/refractory CRLF2 rearranged B-cell acute lymphoblastic leukemia. American journal of hematology 98: E142-E144, 2023.
- Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 201: e37-e41, 2023.
- Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica 108: 1163-1167, 2023.
- Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98: E35-E37, 2023.
- Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. Myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA matched and haploidentical transplantation: results of a phase II study. Haematologica 107: 2496-2500, 2022.
- Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites. Am J Hematol 96: E455-E457, 2021.
- Short NJ, Konopleva M, Kadia T, Kebriaei P, Daver N, Huang X, Masarova L, Cook R, Jain N, Jabbour E, Kantarjian H, Ravandi F. An effective chemotherapy-free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Am J Hematol 96: E229-E232, 2021.
- Koller P, Saliba RM, Ledesma C, Rondon G, Popat U, Alousi A, Mehta R, Oran B, Olson A, Hosing C, Qazilbash M, Khouri I, Ciurea S, Shpall E, Jorgensen J, Wang S, Jain N, Jabbour E, Kantarjian H, Champlin R, Konopleva M, Kebriaei P. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 56: 1746-1749, 2021.
- Saliba RM, Veltri L, Rondon G, Chen J, Al-Atrash G, Alousi A, Martinez C, Augustine L, Hosing CM, Oran B, Rezvani K, Shpall EJ, Kebriaei P, Khouri IF, Popat U, Champlin RE, Ciurea SO. Impact of graft composition on outcomes of haploidentical bone marrow stem cell transplantation. Haematologica 106: 269-274, 2021.
Patient Reviews
CV information above last modified July 22, 2026